Niraparib Clinical Trials

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 12, 2026.

199

Total Trials

Recruiting

Completed

34,500

Total Enrollment

States

Niraparib Evidence & Publications

195 peer-reviewed publications + per-arm primary-outcome data from 20 pivotal trials.

See published evidence →

Niraparib Clinical Trials

Sortable list of all 199 Niraparib trials — recruiting status, pivotal acronyms, indication grouping, NCT links.

See all trials →

What Is Niraparib?

Niraparib is an FDA-approved medication for the treatment of platinum-sensitive ovarian serous carcinoma. It is a type of drug known as a Poly(ADP-ribose) polymerase inhibitor, or PARP inhibitor. Niraparib works by blocking DNA repair mechanisms in cancer cells. Specifically, it impairs the repair of single-strand DNA breaks, which can lead to more severe double-strand DNA breaks. This action can ultimately cause cancer cells to die, particularly those with defects in the homologous recombination (HR) pathway.

Beyond its approved use, niraparib is being investigated in clinical trials for various other cancers. These include other forms of ovarian cancer, breast cancer, fallopian tube cancer, glioblastoma, metastatic colorectal cancer, endometrial serous carcinoma, prostate cancer, bladder cancer, pancreatic cancer, nasopharyngeal carcinoma, and solid tumors that have metastasized to the central nervous system.

Uses and Conditions Under Study

Niraparib is being studied for its potential to treat a wide range of cancers, often focusing on its ability to target DNA repair pathways in tumor cells.

Ovarian and Fallopian Tube Cancers: Niraparib is extensively studied for ovarian cancer, including Ovarian Cancer (36 trials), Ovarian Neoplasms (14 trials), Fallopian Tube Cancer (11 trials), Epithelial Ovarian Cancer (6 trials), and Recurrent Ovarian Carcinoma (5 trials). These trials investigate niraparib's role in managing these gynecological cancers, where it is already approved for platinum-sensitive ovarian serous carcinoma.
Breast Cancer: There are 12 trials investigating niraparib for Breast Cancer. Studies include its use in metastatic triple-negative breast cancer and in combination with other therapies for HER2-negative and BRCA-mutated breast cancer.
Glioblastoma and Glioma: Niraparib is being explored for brain cancers, with trials for newly diagnosed, MGMT unmethylated Glioblastoma Multiforme and progressive IDH1 or IDH2 mutant Glioma. These studies aim to determine if niraparib can improve overall survival in these aggressive brain tumors.
Endometrial Cancers: Given its molecular similarities to high-grade serous ovarian carcinoma, niraparib is under investigation for Endometrial Serous Carcinoma. This includes its use as maintenance therapy or for recurrent disease, with serous endometrial carcinoma showing promise for PARP inhibitor treatment.
Prostate Cancer: Trials are evaluating niraparib in Prostate Cancer, particularly in patients with metastatic disease and specific genomic alterations, sometimes in combination with other established treatments like abiraterone acetate plus prednisone.
Other Solid Tumors: Niraparib is also being studied for a variety of other solid tumors, including Metastatic Colorectal Cancer, Bladder Cancer, Pancreatic Cancer, and Nasopharyngeal Carcinoma. Some trials focus on its efficacy in cancers that have metastasized to the central nervous system. Overall, Solid Tumor (6 trials), Neoplasms (11 trials), and Metastatic Cancer (5 trials) represent broader categories where niraparib's activity is being assessed.

Dosing

Niraparib is primarily administered orally, available in both tablet and capsule forms. The dosage can vary based on individual patient characteristics such as weight, platelet count, and whether it is used in combination with other medications.

In clinical studies, niraparib tablets have been administered daily at doses of 100 mg, 200 mg, or 300 mg. For niraparib capsules (WJB001), a wider range of strengths has been studied, including 40 mg, 60 mg, 80 mg, 100 mg, 120 mg, and 160 mg. These capsules are typically taken once daily (QD), sometimes on specific schedules such as Days 1-5, 8-12, and 15-19, or other frequencies within a 21-day cycle.

Niraparib is often studied as a monotherapy or in combination with other treatments. For example, it has been investigated alongside taxanes, platinum-based chemotherapy, paclitaxel, carboplatin, other PARP inhibitors, VEGF inhibitors, and anti-PD-1/VEGF bispecific antibodies. Specific combination regimens, such as niraparib with dostarlimab and radiation therapy, or niraparib with temozolomide, are also being explored to assess their safety and effectiveness across different cancer types.

Side Effects

In clinical trials involving over 2000 patients, Niraparib was compared to placebo. The most common side effects reported were:

Anemia, affecting 47.4% of patients taking Niraparib compared to 16.8% on placebo.
Nausea, experienced by 41.6% of patients on Niraparib versus 18.8% on placebo.
Constipation, reported by 31.5% of patients on Niraparib compared to 14.4% on placebo.
Fatigue, occurring in 29.4% of patients on Niraparib versus 20.8% on placebo.
Thrombocytopenia, observed in 25.9% of patients on Niraparib compared to 4.7% on placebo.
Hypertension, affecting 23.1% of patients on Niraparib versus 15.1% on placebo.
Vomiting, reported by 18.6% of patients on Niraparib compared to 8.9% on placebo.
Neutropenia, seen in 17.3% of patients on Niraparib versus 5.7% on placebo.

Arthralgia (joint pain) was reported by 14.6% of patients on Niraparib, which was slightly lower than the 15.8% on placebo.

Clinical Trial Results

Ovarian Cancer

In a maintenance study for patients with platinum-sensitive ovarian cancer (NCT01847274), Progression-Free Survival (PFS) was significantly longer for patients taking Niraparib. Patients with a germline BRCA mutation had a median PFS of 21 months with Niraparib, compared to 5.5 months with placebo. For patients without a germline BRCA mutation but with Homologous Recombination Deficiency-positive (HRD+) tumors, median PFS was 12.9 months with Niraparib versus 3.8 months with placebo. For all patients without a germline BRCA mutation, median PFS was 9.3 months with Niraparib compared to 3.9 months with placebo. The chemotherapy-free interval was also extended for patients with a germline BRCA mutation, with a median of 20.0 months for Niraparib compared to 9.4 months for placebo.

In a study of Niraparib in patients with ovarian cancer who had received three or four previous chemotherapy regimens (NCT02354586), Niraparib 300 mg showed an Objective Response Rate (ORR) of 27.66%. The Disease Control Rate (DCR) for these patients was 49.02%, with a median Duration of Response (DoR) of 9.4 months.

For patients with advanced ovarian cancer following response to front-line platinum-based chemotherapy (NCT02655016), Niraparib maintenance treatment extended Prog

Currently Recruiting Trials

There are currently 34 clinical trials recruiting participants to further investigate Niraparib. These studies span various cancer types and research questions, aiming to understand its safety, efficacy, and optimal use. Many trials focus on ovarian cancer. For instance, the University of Miami is conducting a Phase 4 study (NCT06412120) for 70 participants, exploring how genetic and environmental factors influence niraparib maintenance treatment. MedSIR is sponsoring a Phase 2 study (NCT06180356) for 30 patients with oligometastatic ovarian cancer, assessing niraparib rechallenge after surgery. The NICHOL TRIAL (NCT06594679), a Phase 1/2 study by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, is enrolling 73 patients to find the best dose of niraparib combined with abemaciclib. A large Phase 3 trial (NCT05009082) by AGO Study Group is recruiting 970 participants to compare niraparib alone versus niraparib plus bevacizumab in advanced ovarian cancer. Niraparib is also being studied for other solid tumors. The Ivy Brain Tumor Center is leading a Phase 3 study (NCT06388733) for 450 adults with newly diagnosed glioblastoma, comparing niraparib with temozolomide. For pancreatic adenocarcinoma, Abramson Cancer Center at Penn Medicine has a Phase 2 study (NCT06747845) for 68 patients, evaluating niraparib plus ipilimumab. In prostate cancer, M.D. Anderson Cancer Center is conducting a Phase 2 study (NCT04947254) for 200 participants, investigating niraparib with androgen ablation therapy after radiation. Studies for head and neck squamous cell carcinoma include a Phase 1/2 trial (NCT05784012) by Grupo Español de Tratamiento de Tumores de Cabeza y Cuello for 34 patients, combining niraparib and dostarlimab with chemoradiotherapy. Beyond specific cancers, platform trials are exploring niraparib in broader populations. The Canadian Cancer Trials Group is running a Phase 2 platform study (NCT05601440) for 484 patients with metastatic breast cancer, where niraparib plus fulvestrant is one of several substudies. The DRUP Trial (NCT02925234) by The Netherlands Cancer Institute, a Phase 2 study with 1550 participants, includes niraparib among many targeted therapies for advanced cancers with actionable variants. Another Phase 2 platform study (NCT04423185) by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, is enrolling 770 patients with advanced rare solid tumors, including an arm for niraparib in BRCA mutation or HRD cases.
Where to Participate
Clinical trials for Niraparib are conducted across a broad geographic area, with studies active at 92 sites in 71 cities across 32 states. The top cities with the most recruiting sites include:

Houston, Texas (5 sites)

Seattle, Washington (4 sites)

Boston, Massachusetts (4 sites)

Philadelphia, Pennsylvania (3 sites)

Portland, Oregon (3 sites)

La Jolla, California (3 sites)

Cleveland, Ohio (3 sites)

Tampa, Florida (3 sites)

Minneapolis, Minnesota (3 sites)

New York, New York (3 sites)

Eligibility for these trials generally includes participants aged 18 to 99 years, of all genders. Healthy volunteers are not typically included in these studies, but some trials may enroll children.
Development Timeline
The journey for Niraparib began on January 5, 2010, with the initiation of its first clinical trial. Since then, a robust development program has unfolded, encompassing a total of 199 trials and enrolling approximately 34,500 participants. Early development was significantly driven by sponsors like Tesaro, Inc., Janssen Research & Development, LLC, and GlaxoSmithKline. The pipeline expanded rapidly, with the majority of studies progressing through Phase 2 (100 trials) and Phase 1, alongside numerous Phase 1/Phase 2 and Phase 3 investigations. Niraparib's therapeutic scope has broadened considerably over time. Initially, conditions like IBS-C and hyperphosphatemia were explored, but the focus quickly shifted to oncology. The drug's development expanded to target various cancers, including breast cancer, fallopian tube cancer, ovarian cancer, and primary peritoneal carcinoma. Later, its application grew to include pancreatic cancer, prostate cancer, endometrial cancer, glioblastoma, and head and neck squamous cell carcinoma, reflecting a continuous effort to explore its potential across a diverse range of solid tumors, particularly those with DNA repair deficiencies. The latest trial was initiated on July 11, 2025, indicating ongoing research and future potential.

Niraparib Development Timeline

Clinical trial activity from 2010 to 2026.

2026

NCT06412120PHASE4recruiting

Study Evaluating Safety, Tolerability, and Metabolism of Niraparib

70 enrolled

2025

NCT06392841PHASE2withdrawn

Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations

0 enrolled

NCT06682780PHASE1/PHASE2recruiting

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

320 enrolled

NCT07059676not yet recruiting

Design and Validation of Plasma Proteins and Cytokine Panels to Identify Markers Associated With Response to Niraparib as Maintenance Treatment After First-line Platinum-based Regimen in Patients With Advanced Ovarian Cancer

120 enrolled

NCT06953323PHASE1/PHASE2recruiting

A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors

86 enrolled

NCT06915025PHASE3recruiting

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

500 enrolled

NCT06747845PHASE2recruiting

Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy

68 enrolled

NCT06527690PHASE2withdrawn

Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer

0 enrolled

NCT06887933PHASE4not yet recruiting

A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer

67 enrolled

NCT05672095PHASE1/PHASE2withdrawn

Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer

0 enrolled

NCT06365970PHASE2withdrawn

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

0 enrolled

2024

NCT06180356PHASE2recruiting

Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression

30 enrolled

NCT06329830PHASE1/PHASE2withdrawn

177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer

0 enrolled

NCT06433219PHASE2active not recruiting

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

63 enrolled

NCT06258018PHASE1/PHASE2not yet recruiting

Niraparib and Temozolomide in Patients Glioblastoma

86 enrolled

NCT06594679PHASE1/PHASE2recruiting

A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)

73 enrolled

NCT06614790recruiting

Niraparib Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, OC. The First Poland RWE Study.

300 enrolled

NCT05615818PHASE3recruiting

Personalized Medicine for Advanced Biliary Cancer Patients

800 enrolled

NCT05990192PHASE2recruiting

SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy

42 enrolled

NCT06388733PHASE3recruiting

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

450 enrolled

NCT05289648EARLY_PHASE1withdrawn

Niraparib in High-grade Endometrial Cancer Trial

0 enrolled

NCT06212583PHASE2active not recruiting

High-Risk Metachronous Oligometastatic Prostate Cancer Trial

88 enrolled

NCT05689021PHASE2active not recruiting

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

8 enrolled

NCT06237205PHASE2not yet recruiting

Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency

33 enrolled

NCT06161493PHASE1withdrawn

ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors

0 enrolled

2023

NCT05718323PHASE2recruiting

Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC

44 enrolled

NCT05174455PHASE2withdrawn

Niraparib for the Treatment of Leiomyosarcoma

0 enrolled

NCT05784012PHASE1/PHASE2active not recruiting

Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma

34 enrolled

NCT06141265PHASE2recruiting

Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab

116 enrolled

NCT05126342PHASE2withdrawn

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

0 enrolled

NCT06077877PHASE1/PHASE2active not recruiting

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

42 enrolled

NCT05870761PHASE2active not recruiting

Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma

8 enrolled

NCT05666349PHASE1withdrawn

Reirradiation and Niraparib in Patients With Recurrent Glioblastoma

0 enrolled

NCT05412706PHASE2withdrawn

Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy

0 enrolled

NCT05961124PHASE2recruiting

Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer

40 enrolled

NCT05601440PHASE2recruiting

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

484 enrolled

NCT05700721PHASE2recruiting

Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

120 enrolled

NCT04149145PHASE1withdrawn

Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer

0 enrolled

NCT05694715PHASE1recruiting

Combination Therapy in Cancers With Mutations in DNA Repair Genes

24 enrolled

NCT05406700EARLY_PHASE1active not recruiting

Niraparib In Recurrent IDH 1/2 Gliomas

16 enrolled

NCT05519670PHASE1/PHASE2not yet recruiting

A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr

72 enrolled

NCT05065021PHASE2unknown

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

40 enrolled

NCT05523440PHASE2terminated

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

9 enrolled

NCT05238831EARLY_PHASE1withdrawn

SMMART Adaptive Clinical Treatment (ACT) Trial

0 enrolled

2022

NCT05641506PHASE2unknown

A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer

50 enrolled

NCT05526989PHASE2recruiting

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

25 enrolled

NCT05442749PHASE2terminated

Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer

2 enrolled

NCT05009082PHASE3recruiting

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

970 enrolled

NCT05461690PHASE2unknown

Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency

50 enrolled

NCT05515575PHASE2active not recruiting

A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA

8 enrolled

NCT05335993PHASE2active not recruiting

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

10 enrolled

NCT05455424PHASE2completed

Niraparib Efficacy in Patient With Unresectable Mesothelioma

88 enrolled

NCT04926324PHASE1/PHASE2terminated

A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers

3 enrolled

NCT05385068PHASE2unknown

A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi

35 enrolled

NCT05162196PHASE2unknown

The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer

57 enrolled

NCT05297864PHASE2terminated

PARP Inhibition for Gliomas (PI-4G or π4g)

15 enrolled

NCT05401214approved for marketing

Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)

0 enrolled

NCT05232006PHASE2not yet recruiting

PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers

12 enrolled

NCT06964165PHASE2terminated

A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)

36 enrolled

NCT04992013PHASE2active not recruiting

Niraparib in Tumors Metastatic to the CNS

20 enrolled

NCT05311579PHASE2unknown

Niraparib Plus Anlotinib for Recurrent Ovarian Cancer

36 enrolled

NCT05169437PHASE2terminated

Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

22 enrolled

NCT05261269PHASE1completed

A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer

30 enrolled

NCT05183984PHASE2recruiting

Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer

390 enrolled

NCT05187208PHASE4unknown

PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer

102 enrolled

NCT05198804PHASE1/PHASE2completed

A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

117 enrolled

2021

NCT05130515PHASE2completed

Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.

6 enrolled

NCT05076513EARLY_PHASE1active not recruiting

Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma

42 enrolled

NCT04673448PHASE1active not recruiting

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

18 enrolled

NCT04895046PHASE2withdrawn

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

0 enrolled

NCT04812366PHASE2recruiting

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

315 enrolled

NCT05021562completed

A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice

354 enrolled

NCT04991480PHASE1completed

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

93 enrolled

NCT04986371unknown

Real-world Study of Niraparib Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer

300 enrolled

NCT04947254PHASE2recruiting

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

200 enrolled

NCT05162872PHASE2unknown

Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma

99 enrolled

NCT04837209PHASE2active not recruiting

Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

32 enrolled

NCT04734665PHASE2unknown

Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor

44 enrolled

NCT04885413PHASE2unknown

An Open-label, Single Arm, Phase II Trial of Niraparib in Combination With Anti-PD1（Programmed Cell Death Protein 1） Antibody in Recurrent/ Advanced Stage Endometrial Cancer Patients

37 enrolled

NCT04915755PHASE3active not recruiting

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

40 enrolled

NCT04481113PHASE1completed

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

8 enrolled

NCT04716686PHASE2recruiting

Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma

83 enrolled

NCT04861181PHASE4terminated

NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients.

12 enrolled

NCT04641247PHASE2recruiting

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

30 enrolled

NCT04779151PHASE2terminated

Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab

51 enrolled

NCT04764084PHASE1unknown

Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors

52 enrolled

NCT04762901PHASE1withdrawn

LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer

0 enrolled

NCT04774406completed

Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

2,336 enrolled

NCT04681469PHASE2recruiting

Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC

49 enrolled

NCT04701307PHASE2active not recruiting

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

48 enrolled

NCT04715620PHASE2unknown

Niraparib Combined With Radiotherapy in rGBM

30 enrolled

NCT04507841PHASE2active not recruiting

Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

67 enrolled

2020

NCT04592237PHASE2active not recruiting

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

120 enrolled

NCT04493060PHASE2completed

Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

22 enrolled

NCT04940637PHASE2unknown

UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC

70 enrolled

NCT04584255PHASE2active not recruiting

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

62 enrolled

NCT04655183PHASE1/PHASE2withdrawn

Study of M4344 in Combination With Niraparib

0 enrolled

NCT04679064PHASE3unknown

Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

427 enrolled

NCT04159155PHASE2/PHASE3terminated

A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer

11 enrolled

NCT04577833PHASE1active not recruiting

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

136 enrolled

NCT04556071PHASE2unknown

Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer

32 enrolled

NCT04194554PHASE1/PHASE2active not recruiting

A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

102 enrolled

NCT04313504PHASE2completed

Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC

10 enrolled

NCT04475939PHASE3completed

Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer

666 enrolled

NCT04185831PHASE2active not recruiting

A MolEcularly Guided Anti-Cancer Drug Off-Label Trial

167 enrolled

NCT04288687PHASE2completed

A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects

11 enrolled

NCT04544995PHASE1terminated

Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)

47 enrolled

NCT04826198PHASE1/PHASE2terminated

Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months

13 enrolled

NCT06827353recruiting

Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Without Homologous Recombination Deficiency

300 enrolled

NCT04546373completed

Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer

316 enrolled

NCT04497844PHASE3active not recruiting

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

696 enrolled

NCT04508803PHASE2completed

Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer

37 enrolled

NCT04341181PHASE2recruiting

ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

300 enrolled

NCT04502602PHASE1active not recruiting

Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer

18 enrolled

NCT04423185PHASE2recruiting

PLATFORM Study of Precision Medicine for Rare Tumors

770 enrolled

NCT04392102PHASE2completed

A Study of Niraparib in Patients With Relapsed Ovarian Cancer

15 enrolled

NCT04409002PHASE2completed

Niraparib + Dostarlimab + RT in Pancreatic Cancer

18 enrolled

NCT03651206PHASE2/PHASE3recruiting

Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib

138 enrolled

NCT04235101PHASE1completed

Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors

32 enrolled

NCT04240106PHASE2completed

Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)

14 enrolled

NCT04376073PHASE2unknown

Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer

40 enrolled

NCT04217798PHASE2unknown

Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer

36 enrolled

NCT04395612PHASE2unknown

Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer

38 enrolled

NCT04284852PHASE2completed

Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting

20 enrolled

NCT04068753PHASE2active not recruiting

Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer

66 enrolled

NCT04267939PHASE1terminated

ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

14 enrolled

NCT04030559PHASE2terminated

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

11 enrolled

NCT04178460PHASE1terminated

A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment

60 enrolled

2019

NCT03806049PHASE3withdrawn

Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer

0 enrolled

NCT04080284PHASE2completed

Trial of Maintenance With Niraparib- Uterine Serous Carcinoma

22 enrolled

NCT04221503PHASE2active not recruiting

Niraparib/TTFields in GBM

30 enrolled

NCT04170153PHASE1active not recruiting

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

161 enrolled

NCT06086665completed

The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer

850 enrolled

NCT03891576PHASE2terminated

Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)

83 enrolled

NCT03983226PHASE2recruiting

Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)

167 enrolled

NCT03983993PHASE2active not recruiting

Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer

26 enrolled

NCT03425201PHASE1/PHASE2completed

Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA)

67 enrolled

NCT04037254PHASE1/PHASE2completed

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

22 enrolled

NCT03955471PHASE2terminated

Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer

41 enrolled

NCT03368729PHASE1/PHASE2active not recruiting

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

46 enrolled

NCT03945084PHASE2completed

Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy

58 enrolled

NCT03981796PHASE3active not recruiting

A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

785 enrolled

NCT03945721PHASE1active not recruiting

A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients

21 enrolled

NCT03840967PHASE2terminated

A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma

14 enrolled

NCT03891615PHASE1unknown

Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer

30 enrolled

NCT03869190PHASE1/PHASE2completed

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

272 enrolled

NCT03586661PHASE1active not recruiting

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

31 enrolled

NCT03752216PHASE4completed

NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.

141 enrolled

NCT03925350PHASE2unknown

Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation

41 enrolled

NCT03830918PHASE1/PHASE2active not recruiting

Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

59 enrolled

NCT03768063PHASE3active not recruiting

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

1,000 enrolled

NCT03903835PHASE3recruiting

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

750 enrolled

NCT03654833PHASE2unknown

Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma

186 enrolled

NCT03748641PHASE3active not recruiting

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

765 enrolled

NCT03553004PHASE2unknown

Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial

18 enrolled

NCT03895788PHASE1unknown

A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer

24 enrolled

NCT03695380PHASE1completed

A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer

77 enrolled

NCT05734911completed

Effectiveness and Safety of Niraparib as First-line Maintenance Therapy for Ovarian Cancer: a Real-world Study

199 enrolled

2018

NCT03759587PHASE2completed

Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer

19 enrolled

NCT03759600PHASE2completed

Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer

20 enrolled

NCT03783949PHASE2completed

European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer

122 enrolled

NCT03598270PHASE3completed

Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer

417 enrolled

NCT05751629PHASE2completed

Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer

41 enrolled

NCT03574779PHASE2completed

A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer

77 enrolled

NCT03602859PHASE3active not recruiting

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

1,400 enrolled

NCT03601923PHASE2completed

Niraparib in Patients With Pancreatic Cancer

32 enrolled

NCT03207347PHASE2completed

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

37 enrolled

NCT02826512PHASE2terminated

A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients

9 enrolled

NCT03329937PHASE1completed

Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer

21 enrolled

NCT03497429PHASE1completed

A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors

9 enrolled

NCT03431350PHASE2active not recruiting

A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

136 enrolled

NCT03359850PHASE1completed

Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients

17 enrolled

NCT03404960PHASE1/PHASE2completed

Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy

104 enrolled

2017

NCT03551171PHASE1completed

The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer

42 enrolled

NCT03326193PHASE2completed

A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

105 enrolled

NCT03329001PHASE1completed

Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule

236 enrolled

NCT03088059PHASE2unknown

Biomarker-based Study in R/M SCCHN

340 enrolled

NCT03016338PHASE2unknown

Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer

51 enrolled

NCT03209401PHASE1terminated

Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies

23 enrolled

NCT03307785PHASE1completed

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

60 enrolled

NCT03308942PHASE2completed

Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants

53 enrolled

NCT03076203PHASE1completed

Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)

14 enrolled

NCT03221400PHASE1/PHASE2unknown

PEN-866 in Patients With Advanced Solid Malignancies

340 enrolled

NCT04785716completed

Real-life Use of Niraparib in a Patient Access Program in Norway

106 enrolled

NCT03154281PHASE1completed

Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

14 enrolled

NCT03025867approved for marketing

Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer

0 enrolled

2016

NCT02924766PHASE1completed

A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)

34 enrolled

NCT02925234PHASE2recruiting

The Drug Rediscovery Protocol (DRUP Trial)

1,550 enrolled

NCT02854436PHASE2completed

An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

289 enrolled

NCT02655016PHASE3active not recruiting

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

733 enrolled

NCT02657889PHASE1/PHASE2completed

Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer

122 enrolled

NCT02500901PHASE1terminated

Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)

2 enrolled

2015

NCT02354586PHASE2completed

A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

463 enrolled

NCT02476552PHASE1completed

Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With Cancer

12 enrolled

NCT02354131PHASE1/PHASE2completed

Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer

108 enrolled

2014

NCT02044120PHASE1completed

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma

34 enrolled

NCT01905592PHASE3terminated

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

216 enrolled

2013

NCT01847274PHASE3completed

A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

596 enrolled

2010

NCT01042379PHASE2recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

5,000 enrolled

Conditions Under Study

Condition	NCT ID	Title	Status	Phase	Enrollment
Ovarian Cancer	NCT06412120	Study Evaluating Safety, Tolerability, and Metabolism of Niraparib	recruiting	PHASE4	70
	NCT06915025	Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer	recruiting	PHASE3	500
	NCT06180356	Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression	recruiting	PHASE2	30
	NCT06433219	Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)	active not recruiting	PHASE2	63
	NCT06594679	A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)	recruiting	PHASE1/PHASE2	73
	NCT06614790	Niraparib Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, OC. The First Poland RWE Study.	recruiting	N/A	300
	NCT06161493	ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors	withdrawn	PHASE1	0
	NCT05961124	Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer	recruiting	PHASE2	40
	NCT05065021	Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor	unknown	PHASE2	40
	NCT05641506	A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer	unknown	PHASE2	50
	NCT05009082	Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer	recruiting	PHASE3	970
	NCT05183984	Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer	recruiting	PHASE2	390
	NCT05187208	PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer	unknown	PHASE4	102
	NCT05198804	A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer	completed	PHASE1/PHASE2	117
	NCT05021562	A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice	completed	N/A	354
	NCT04507841	Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer	active not recruiting	PHASE2	67
	NCT04679064	Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment	unknown	PHASE3	427
	NCT04826198	Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months	terminated	PHASE1/PHASE2	13
	NCT04502602	Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer	active not recruiting	PHASE1	18
	NCT04392102	A Study of Niraparib in Patients With Relapsed Ovarian Cancer	completed	PHASE2	15
	NCT04217798	Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer	unknown	PHASE2	36
	NCT04284852	Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting	completed	PHASE2	20
	NCT04267939	ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer	terminated	PHASE1	14
	NCT03806049	Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer	withdrawn	PHASE3	0
	NCT03891576	Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)	terminated	PHASE2	83
	NCT03752216	NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.	completed	PHASE4	141
	NCT03895788	A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer	unknown	PHASE1	24
	NCT03695380	A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer	completed	PHASE1	77
	NCT03759587	Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer	completed	PHASE2	19
	NCT03759600	Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer	completed	PHASE2	20
	NCT03783949	European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer	completed	PHASE2	122
	NCT03551171	The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer	completed	PHASE1	42
	NCT04785716	Real-life Use of Niraparib in a Patient Access Program in Norway	completed	N/A	106
	NCT03154281	Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast	completed	PHASE1	14
	NCT02657889	Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer	completed	PHASE1/PHASE2	122
	NCT02354586	A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens	completed	PHASE2	463
	NCT02354131	Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer	completed	PHASE1/PHASE2	108
Ovarian Neoplasms	NCT06887933	A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer	not yet recruiting	PHASE4	67
	NCT06964165	A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)	terminated	PHASE2	36
	NCT04641247	A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study	recruiting	PHASE2	30
	NCT04556071	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	unknown	PHASE2	32
	NCT03955471	Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer	terminated	PHASE2	41
	NCT05734911	Effectiveness and Safety of Niraparib as First-line Maintenance Therapy for Ovarian Cancer: a Real-world Study	completed	N/A	199
	NCT03574779	A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer	completed	PHASE2	77
	NCT03602859	A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer	active not recruiting	PHASE3	1,400
	NCT03359850	Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients	completed	PHASE1	17
	NCT03326193	A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy	completed	PHASE2	105
	NCT02655016	A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy	active not recruiting	PHASE3	733
	NCT02354586	A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens	completed	PHASE2	463
	NCT01905592	A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients	terminated	PHASE3	216
	NCT01847274	A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer	completed	PHASE3	596
Breast Cancer	NCT05601440	Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer	recruiting	PHASE2	484
	NCT05519670	A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr	not yet recruiting	PHASE1/PHASE2	72
	NCT04991480	A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors	completed	PHASE1	93
	NCT04837209	Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer	active not recruiting	PHASE2	32
	NCT04762901	LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer	withdrawn	PHASE1	0
	NCT04584255	Niraparib + Dostarlimab In BRCA Mutated Breast Cancer	active not recruiting	PHASE2	62
	NCT04655183	Study of M4344 in Combination With Niraparib	withdrawn	PHASE1/PHASE2	0
	NCT04240106	Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)	completed	PHASE2	14
	NCT02826512	A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients	terminated	PHASE2	9
	NCT03154281	Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast	completed	PHASE1	14
	NCT02657889	Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer	completed	PHASE1/PHASE2	122
	NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	recruiting	PHASE2	5,000
Fallopian Tube Cancer	NCT06915025	Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer	recruiting	PHASE3	500
	NCT05065021	Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor	unknown	PHASE2	40
	NCT05009082	Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer	recruiting	PHASE3	970
	NCT05198804	A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer	completed	PHASE1/PHASE2	117
	NCT04546373	Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer	completed	N/A	316
	NCT03891576	Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)	terminated	PHASE2	83
	NCT03983226	Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)	recruiting	PHASE2	167
	NCT03759587	Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer	completed	PHASE2	19
	NCT03759600	Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer	completed	PHASE2	20
	NCT03783949	European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer	completed	PHASE2	122
	NCT02657889	Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer	completed	PHASE1/PHASE2	122
Neoplasms	NCT06077877	A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors	active not recruiting	PHASE1/PHASE2	42
	NCT04556071	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	unknown	PHASE2	32
	NCT04544995	Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)	terminated	PHASE1	47
	NCT04341181	ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling	recruiting	PHASE2	300
	NCT03981796	A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer	active not recruiting	PHASE3	785
	NCT03359850	Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients	completed	PHASE1	17
	NCT03329001	Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule	completed	PHASE1	236
	NCT03307785	Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042	completed	PHASE1	60
	NCT03308942	Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants	completed	PHASE2	53
	NCT03221400	PEN-866 in Patients With Advanced Solid Malignancies	unknown	PHASE1/PHASE2	340
	NCT02657889	Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer	completed	PHASE1/PHASE2	122
Solid Tumor	NCT05169437	Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors	terminated	PHASE2	22
	NCT04185831	A MolEcularly Guided Anti-Cancer Drug Off-Label Trial	active not recruiting	PHASE2	167
	NCT04235101	Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors	completed	PHASE1	32
	NCT03359850	Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients	completed	PHASE1	17
	NCT03307785	Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042	completed	PHASE1	60
	NCT03221400	PEN-866 in Patients With Advanced Solid Malignancies	unknown	PHASE1/PHASE2	340
Epithelial Ovarian Cancer	NCT06915025	Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer	recruiting	PHASE3	500
	NCT05385068	A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi	unknown	PHASE2	35
	NCT05187208	PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer	unknown	PHASE4	102
	NCT04986371	Real-world Study of Niraparib Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer	unknown	N/A	300
	NCT04546373	Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer	completed	N/A	316
	NCT06086665	The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer	completed	N/A	850
Cancer	NCT04774406	Arterial Hypertension Related to PARP Inhibitors (ArteRIB)	completed	N/A	2,336
	NCT04341181	ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling	recruiting	PHASE2	300
	NCT03768063	A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study	active not recruiting	PHASE3	1,000
	NCT02925234	The Drug Rediscovery Protocol (DRUP Trial)	recruiting	PHASE2	1,550
	NCT02476552	Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With Cancer	completed	PHASE1	12
Recurrent Ovarian Carcinoma	NCT05672095	Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer	withdrawn	PHASE1/PHASE2	0
	NCT05523440	Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation	terminated	PHASE2	9
	NCT05238831	SMMART Adaptive Clinical Treatment (ACT) Trial	withdrawn	EARLY_PHASE1	0
	NCT03586661	Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	active not recruiting	PHASE1	31
	NCT03598270	Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer	completed	PHASE3	417
Metastatic Cancer	NCT04992013	Niraparib in Tumors Metastatic to the CNS	active not recruiting	PHASE2	20
	NCT05169437	Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors	terminated	PHASE2	22
	NCT04895046	Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma	withdrawn	PHASE2	0
	NCT04991480	A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors	completed	PHASE1	93
	NCT03307785	Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042	completed	PHASE1	60
Primary Peritoneal Carcinoma	NCT06915025	Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer	recruiting	PHASE3	500
	NCT05198804	A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer	completed	PHASE1/PHASE2	117
	NCT03891576	Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)	terminated	PHASE2	83
	NCT03983226	Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)	recruiting	PHASE2	167
	NCT03783949	European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer	completed	PHASE2	122
Pancreatic Cancer	NCT05169437	Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors	terminated	PHASE2	22
	NCT04764084	Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors	unknown	PHASE1	52
	NCT04409002	Niraparib + Dostarlimab + RT in Pancreatic Cancer	completed	PHASE2	18
	NCT03553004	Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial	unknown	PHASE2	18
	NCT03601923	Niraparib in Patients With Pancreatic Cancer	completed	PHASE2	32
Primary Peritoneal Cancer	NCT05126342	Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi	withdrawn	PHASE2	0
	NCT05065021	Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor	unknown	PHASE2	40
	NCT04546373	Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer	completed	N/A	316
	NCT03759587	Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer	completed	PHASE2	19
	NCT03759600	Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer	completed	PHASE2	20
Triple Negative Breast Cancer	NCT05461690	Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency	unknown	PHASE2	50
	NCT04837209	Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer	active not recruiting	PHASE2	32
	NCT04178460	A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment	terminated	PHASE1	60
	NCT03945721	A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients	active not recruiting	PHASE1	21
	NCT02657889	Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer	completed	PHASE1/PHASE2	122
Recurrent Ovarian Cancer	NCT05126342	Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi	withdrawn	PHASE2	0
	NCT05335993	A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.	active not recruiting	PHASE2	10
	NCT05311579	Niraparib Plus Anlotinib for Recurrent Ovarian Cancer	unknown	PHASE2	36
	NCT03025867	Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer	approved for marketing	N/A	0
Prostate Cancer	NCT06527690	Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer	withdrawn	PHASE2	0
	NCT06212583	High-Risk Metachronous Oligometastatic Prostate Cancer Trial	active not recruiting	PHASE2	88
	NCT04812366	Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer	recruiting	PHASE2	315
	NCT04194554	A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer	active not recruiting	PHASE1/PHASE2	102
Endometrial Cancer	NCT05289648	Niraparib in High-grade Endometrial Cancer Trial	withdrawn	EARLY_PHASE1	0
	NCT05169437	Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors	terminated	PHASE2	22
	NCT04080284	Trial of Maintenance With Niraparib- Uterine Serous Carcinoma	completed	PHASE2	22
	NCT03016338	Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer	unknown	PHASE2	51
Recurrent Glioblastoma	NCT05666349	Reirradiation and Niraparib in Patients With Recurrent Glioblastoma	withdrawn	PHASE1	0
	NCT05297864	PARP Inhibition for Gliomas (PI-4G or π4g)	terminated	PHASE2	15
	NCT04715620	Niraparib Combined With Radiotherapy in rGBM	unknown	PHASE2	30
	NCT04221503	Niraparib/TTFields in GBM	active not recruiting	PHASE2	30
Peritoneal Cancer	NCT05009082	Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer	recruiting	PHASE3	970
	NCT05335993	A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.	active not recruiting	PHASE2	10
	NCT04785716	Real-life Use of Niraparib in a Patient Access Program in Norway	completed	N/A	106
	NCT02657889	Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer	completed	PHASE1/PHASE2	122
Homologous Recombination Deficiency	NCT06527690	Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer	withdrawn	PHASE2	0
	NCT05461690	Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency	unknown	PHASE2	50
	NCT04556071	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	unknown	PHASE2	32
	NCT03209401	Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies	terminated	PHASE1	23
Endometrial Carcinoma	NCT04716686	Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma	recruiting	PHASE2	83
	NCT04159155	A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer	terminated	PHASE2/PHASE3	11
	NCT04178460	A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment	terminated	PHASE1	60
	NCT04080284	Trial of Maintenance With Niraparib- Uterine Serous Carcinoma	completed	PHASE2	22
Advanced Solid Tumor	NCT06682780	A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours	recruiting	PHASE1/PHASE2	320
	NCT06953323	A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors	recruiting	PHASE1/PHASE2	86
	NCT04655183	Study of M4344 in Combination With Niraparib	withdrawn	PHASE1/PHASE2	0
	NCT04502602	Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer	active not recruiting	PHASE1	18
Glioblastoma	NCT06388733	A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma	recruiting	PHASE3	450
	NCT05076513	Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma	active not recruiting	EARLY_PHASE1	42
	NCT04221503	Niraparib/TTFields in GBM	active not recruiting	PHASE2	30
Ovarian Cancer Recurrent	NCT05990192	SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy	recruiting	PHASE2	42
	NCT04149145	Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer	withdrawn	PHASE1	0
	NCT03983226	Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)	recruiting	PHASE2	167
Stage IV Pancreatic Cancer AJCC v8	NCT05238831	SMMART Adaptive Clinical Treatment (ACT) Trial	withdrawn	EARLY_PHASE1	0
	NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18
	NCT04493060	Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer	completed	PHASE2	22
Glioma, Malignant	NCT06258018	Niraparib and Temozolomide in Patients Glioblastoma	not yet recruiting	PHASE1/PHASE2	86
	NCT05406700	Niraparib In Recurrent IDH 1/2 Gliomas	active not recruiting	EARLY_PHASE1	16
	NCT05076513	Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma	active not recruiting	EARLY_PHASE1	42
Cholangiocarcinoma	NCT04895046	Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma	withdrawn	PHASE2	0
	NCT04764084	Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors	unknown	PHASE1	52
	NCT03207347	A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)	completed	PHASE2	37
Advanced Cancer	NCT04991480	A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors	completed	PHASE1	93
	NCT03307785	Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042	completed	PHASE1	60
	NCT03221400	PEN-866 in Patients With Advanced Solid Malignancies	unknown	PHASE1/PHASE2	340
Gastric Adenocarcinoma	NCT04779151	Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab	terminated	PHASE2	51
	NCT04764084	Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors	unknown	PHASE1	52
	NCT03221400	PEN-866 in Patients With Advanced Solid Malignancies	unknown	PHASE1/PHASE2	340
Prostatic Neoplasms	NCT04577833	A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer	active not recruiting	PHASE1	136
	NCT02924766	A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)	completed	PHASE1	34
	NCT02854436	An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies	completed	PHASE2	289
Gastric Cancer	NCT04178460	A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment	terminated	PHASE1	60
	NCT03840967	A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma	terminated	PHASE2	14
	NCT03221400	PEN-866 in Patients With Advanced Solid Malignancies	unknown	PHASE1/PHASE2	340
GBM	NCT06388733	A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma	recruiting	PHASE3	450
	NCT05076513	Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma	active not recruiting	EARLY_PHASE1	42
	NCT04221503	Niraparib/TTFields in GBM	active not recruiting	PHASE2	30
Head and Neck Cancer	NCT05169437	Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors	terminated	PHASE2	22
	NCT04779151	Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab	terminated	PHASE2	51
	NCT04313504	Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC	completed	PHASE2	10
Neoplasms, Breast	NCT04915755	Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease	active not recruiting	PHASE3	40
	NCT03329937	Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer	completed	PHASE1	21
	NCT01905592	A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients	terminated	PHASE3	216
BRCA1 Gene Mutation	NCT06392841	Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations	withdrawn	PHASE2	0
	NCT04030559	Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects	terminated	PHASE2	11
	NCT01905592	A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients	terminated	PHASE3	216
BRCA2 Gene Mutation	NCT06392841	Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations	withdrawn	PHASE2	0
	NCT04030559	Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects	terminated	PHASE2	11
	NCT01905592	A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients	terminated	PHASE3	216
HER2-negative Breast Cancer	NCT04764084	Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors	unknown	PHASE1	52
	NCT04584255	Niraparib + Dostarlimab In BRCA Mutated Breast Cancer	active not recruiting	PHASE2	62
	NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	recruiting	PHASE2	5,000
Metastatic Prostate Cancer	NCT06329830	177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer	withdrawn	PHASE1/PHASE2	0
	NCT02500901	Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)	terminated	PHASE1	2
Stage IV Ovarian Cancer AJCC v8	NCT05238831	SMMART Adaptive Clinical Treatment (ACT) Trial	withdrawn	EARLY_PHASE1	0
	NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18
CHEK2 Gene Mutation	NCT06392841	Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations	withdrawn	PHASE2	0
	NCT04030559	Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects	terminated	PHASE2	11
BRIP1 Gene Mutation	NCT06392841	Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations	withdrawn	PHASE2	0
	NCT04030559	Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects	terminated	PHASE2	11
FANCA Gene Mutation	NCT06392841	Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations	withdrawn	PHASE2	0
	NCT04030559	Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects	terminated	PHASE2	11
Stage IVA Prostate Cancer AJCC v8	NCT04947254	Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer	recruiting	PHASE2	200
	NCT04037254	Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring	completed	PHASE1/PHASE2	22
Prostate Adenocarcinoma	NCT04288687	A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects	completed	PHASE2	11
	NCT04037254	Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring	completed	PHASE1/PHASE2	22
Prostate Carcinoma	NCT04947254	Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer	recruiting	PHASE2	200
	NCT04030559	Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects	terminated	PHASE2	11
Tumors	NCT04341181	ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling	recruiting	PHASE2	300
	NCT02925234	The Drug Rediscovery Protocol (DRUP Trial)	recruiting	PHASE2	1,550
Anatomic Stage III Breast Cancer AJCC v8	NCT05238831	SMMART Adaptive Clinical Treatment (ACT) Trial	withdrawn	EARLY_PHASE1	0
	NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18
Neoplasia	NCT04341181	ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling	recruiting	PHASE2	300
	NCT02925234	The Drug Rediscovery Protocol (DRUP Trial)	recruiting	PHASE2	1,550
Carcinoma	NCT04556071	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	unknown	PHASE2	32
	NCT03221400	PEN-866 in Patients With Advanced Solid Malignancies	unknown	PHASE1/PHASE2	340
Lung Cancer	NCT04940637	UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC	unknown	PHASE2	70
	NCT03891615	Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer	unknown	PHASE1	30
Advanced Malignant Solid Neoplasm	NCT05238831	SMMART Adaptive Clinical Treatment (ACT) Trial	withdrawn	EARLY_PHASE1	0
	NCT03830918	Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy	active not recruiting	PHASE1/PHASE2	59
BRCA1 Mutation	NCT05694715	Combination Therapy in Cancers With Mutations in DNA Repair Genes	recruiting	PHASE1	24
	NCT04556071	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	unknown	PHASE2	32
Urothelial Carcinoma	NCT03945084	Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy	completed	PHASE2	58
	NCT03869190	Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)	completed	PHASE1/PHASE2	272
Mesothelioma	NCT04940637	UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC	unknown	PHASE2	70
	NCT03207347	A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)	completed	PHASE2	37
Mesothelioma, Malignant	NCT05455424	Niraparib Efficacy in Patient With Unresectable Mesothelioma	completed	PHASE2	88
	NCT03654833	Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma	unknown	PHASE2	186
Recurrent Endometrial Carcinoma	NCT05523440	Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation	terminated	PHASE2	9
	NCT03586661	Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	active not recruiting	PHASE1	31
Oligometastatic Disease	NCT06180356	Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression	recruiting	PHASE2	30
	NCT06212583	High-Risk Metachronous Oligometastatic Prostate Cancer Trial	active not recruiting	PHASE2	88
Recurrent Fallopian Tube Cancer	NCT05126342	Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi	withdrawn	PHASE2	0
	NCT05335993	A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.	active not recruiting	PHASE2	10
Recurrent Fallopian Tube Carcinoma	NCT05672095	Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer	withdrawn	PHASE1/PHASE2	0
	NCT03586661	Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	active not recruiting	PHASE1	31
Recurrent Glioma	NCT05406700	Niraparib In Recurrent IDH 1/2 Gliomas	active not recruiting	EARLY_PHASE1	16
	NCT05297864	PARP Inhibition for Gliomas (PI-4G or π4g)	terminated	PHASE2	15
Recurrent Primary Peritoneal Carcinoma	NCT05672095	Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer	withdrawn	PHASE1/PHASE2	0
	NCT03586661	Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	active not recruiting	PHASE1	31
Metastatic Breast Cancer	NCT03368729	Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer	active not recruiting	PHASE1/PHASE2	46
	NCT02657889	Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer	completed	PHASE1/PHASE2	122
BRCA2 Mutation	NCT05694715	Combination Therapy in Cancers With Mutations in DNA Repair Genes	recruiting	PHASE1	24
	NCT04556071	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	unknown	PHASE2	32
Castration-Resistant Prostate Carcinoma	NCT05689021	CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations	active not recruiting	PHASE2	8
	NCT04592237	Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer	active not recruiting	PHASE2	120
Ovarian Carcinoma	NCT05311579	Niraparib Plus Anlotinib for Recurrent Ovarian Cancer	unknown	PHASE2	36
	NCT06827353	Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Without Homologous Recombination Deficiency	recruiting	N/A	300
Metastatic Castration-resistant Prostate Cancer	NCT06329830	177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer	withdrawn	PHASE1/PHASE2	0
	NCT05401214	Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)	approved for marketing	N/A	0
Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma	NCT06141265	Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab	recruiting	PHASE2	116
	NCT03602859	A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer	active not recruiting	PHASE3	1,400
Serous Carcinoma	NCT04716686	Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma	recruiting	PHASE2	83
	NCT04159155	A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer	terminated	PHASE2/PHASE3	11
PALB2 Gene Mutation	NCT06392841	Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations	withdrawn	PHASE2	0
	NCT05694715	Combination Therapy in Cancers With Mutations in DNA Repair Genes	recruiting	PHASE1	24
Pancreatic Adenocarcinoma	NCT03404960	Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy	completed	PHASE1/PHASE2	104
	NCT03221400	PEN-866 in Patients With Advanced Solid Malignancies	unknown	PHASE1/PHASE2	340
Anatomic Stage IV Breast Cancer AJCC v8	NCT05238831	SMMART Adaptive Clinical Treatment (ACT) Trial	withdrawn	EARLY_PHASE1	0
	NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18
Pancreatic Ductal Adenocarcinoma	NCT04779151	Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab	terminated	PHASE2	51
	NCT03221400	PEN-866 in Patients With Advanced Solid Malignancies	unknown	PHASE1/PHASE2	340
Head and Neck Squamous Cell Carcinoma	NCT05784012	Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma	active not recruiting	PHASE1/PHASE2	34
	NCT04681469	Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC	recruiting	PHASE2	49
Endometrial Adenocarcinoma	NCT03586661	Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	active not recruiting	PHASE1	31
	NCT03221400	PEN-866 in Patients With Advanced Solid Malignancies	unknown	PHASE1/PHASE2	340
Platinum-resistant Ovarian Cancer	NCT05198804	A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer	completed	PHASE1/PHASE2	117
	NCT04376073	Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer	unknown	PHASE2	40
Platinum-Resistant Ovarian Carcinoma	NCT05672095	Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer	withdrawn	PHASE1/PHASE2	0
	NCT03586661	Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	active not recruiting	PHASE1	31
Stage IIC Prostate Cancer AJCC v8	NCT04947254	Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer	recruiting	PHASE2	200
	NCT04037254	Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring	completed	PHASE1/PHASE2	22
Breast Neoplasms	NCT04641247	A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study	recruiting	PHASE2	30
	NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	recruiting	PHASE2	5,000
Stage III Lung Cancer AJCC v8	NCT04701307	Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas	active not recruiting	PHASE2	48
	NCT03830918	Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy	active not recruiting	PHASE1/PHASE2	59
ATM Gene Mutation	NCT05694715	Combination Therapy in Cancers With Mutations in DNA Repair Genes	recruiting	PHASE1	24
	NCT04030559	Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects	terminated	PHASE2	11
Stage III Ovarian Cancer AJCC v8	NCT05238831	SMMART Adaptive Clinical Treatment (ACT) Trial	withdrawn	EARLY_PHASE1	0
	NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18
Stage III Pancreatic Cancer AJCC v8	NCT05238831	SMMART Adaptive Clinical Treatment (ACT) Trial	withdrawn	EARLY_PHASE1	0
	NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18
Stage III Prostate Cancer AJCC v8	NCT04947254	Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer	recruiting	PHASE2	200
	NCT04037254	Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring	completed	PHASE1/PHASE2	22
Stage IIIA Lung Cancer AJCC v8	NCT04701307	Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas	active not recruiting	PHASE2	48
	NCT03830918	Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy	active not recruiting	PHASE1/PHASE2	59
Stage IIIA Prostate Cancer AJCC v8	NCT04947254	Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer	recruiting	PHASE2	200
	NCT04037254	Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring	completed	PHASE1/PHASE2	22
Stage IIIB Lung Cancer AJCC v8	NCT04701307	Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas	active not recruiting	PHASE2	48
	NCT03830918	Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy	active not recruiting	PHASE1/PHASE2	59
Stage IIIB Prostate Cancer AJCC v8	NCT04947254	Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer	recruiting	PHASE2	200
	NCT04037254	Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring	completed	PHASE1/PHASE2	22
Metastatic Pancreatic Cancer	NCT05442749	Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer	terminated	PHASE2	2
	NCT04409002	Niraparib + Dostarlimab + RT in Pancreatic Cancer	completed	PHASE2	18
Stage IIIC Lung Cancer AJCC v8	NCT04701307	Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas	active not recruiting	PHASE2	48
	NCT03830918	Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy	active not recruiting	PHASE1/PHASE2	59
Stage IIIC Prostate Cancer AJCC v8	NCT04947254	Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer	recruiting	PHASE2	200
	NCT04037254	Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring	completed	PHASE1/PHASE2	22
High Grade Ovarian Serous Adenocarcinoma	NCT05961124	Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer	recruiting	PHASE2	40
	NCT03586661	Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	active not recruiting	PHASE1	31
Esophageal Cancer	NCT05169437	Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors	terminated	PHASE2	22
	NCT03840967	A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma	terminated	PHASE2	14
Hormone-refractory Prostate Cancer	NCT03076203	Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)	completed	PHASE1	14
Hormone Receptor Negative Tumor	NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	recruiting	PHASE2	5,000
Hormone Receptor Positive Breast Adenocarcinoma	NCT04481113	Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer	completed	PHASE1	8
Hormone Receptor Positive Tumor	NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	recruiting	PHASE2	5,000
HRD	NCT04895046	Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma	withdrawn	PHASE2	0
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast	NCT01905592	A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients	terminated	PHASE3	216
IDH1 Mutation	NCT05406700	Niraparib In Recurrent IDH 1/2 Gliomas	active not recruiting	EARLY_PHASE1	16
IDH2 Gene Mutation	NCT05406700	Niraparib In Recurrent IDH 1/2 Gliomas	active not recruiting	EARLY_PHASE1	16
Invasive Breast Carcinoma	NCT04481113	Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer	completed	PHASE1	8
Locally Advanced Breast Cancer	NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	recruiting	PHASE2	5,000
Locally Advanced Leiomyosarcoma	NCT05174455	Niraparib for the Treatment of Leiomyosarcoma	withdrawn	PHASE2	0
Locally Advanced Solid Tumor	NCT05169437	Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors	terminated	PHASE2	22
Low-grade Glioma	NCT05406700	Niraparib In Recurrent IDH 1/2 Gliomas	active not recruiting	EARLY_PHASE1	16
Lung Cancer, Non-Small Cell	NCT04475939	Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer	completed	PHASE3	666
Lung Small Cell Carcinoma	NCT04701307	Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas	active not recruiting	PHASE2	48
Lung Tumor	NCT05169437	Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors	terminated	PHASE2	22
Melanoma	NCT05169437	Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors	terminated	PHASE2	22
Metastatic BRCA Hereditary Breast Carcinoma	NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18
Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers	NCT05232006	PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers	not yet recruiting	PHASE2	12
Metastatic Breast Carcinoma	NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18
Metastatic Castration-resistant Prostate Cancer (mCRPC)	NCT03903835	ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer	recruiting	PHASE3	750
Metastatic Castration-sensitive Prostate Cancer	NCT04497844	A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)	active not recruiting	PHASE3	696
Metastatic Colorectal Cancer	NCT05412706	Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy	withdrawn	PHASE2	0
Metastatic Fallopian Tube Carcinoma	NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)	NCT06392841	Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations	withdrawn	PHASE2	0
	NCT03903835	ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer	recruiting	PHASE3	750
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)	NCT06392841	Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations	withdrawn	PHASE2	0
	NCT03903835	ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer	recruiting	PHASE3	750
Metastatic Leiomyosarcoma	NCT05174455	Niraparib for the Treatment of Leiomyosarcoma	withdrawn	PHASE2	0
Metastatic Malignant Solid Neoplasm	NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18
Metastatic Melanoma	NCT03925350	Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation	unknown	PHASE2	41
Metastatic Microsatellite Stable Colorectal Carcinoma	NCT03983993	Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer	active not recruiting	PHASE2	26
Metastatic or Locally Advanced Unresectable Solid Tumors	NCT04170153	Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)	active not recruiting	PHASE1	161
Metastatic Ovarian Carcinoma	NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18
Metastatic Pancreatic Carcinoma	NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18
Metastatic Pancreatic Ductal Adenocarcinoma	NCT04493060	Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer	completed	PHASE2	22
Metastatic Primary Peritoneal Carcinoma	NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18
Metastatic Prostate Adenocarcinoma	NCT05689021	CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations	active not recruiting	PHASE2	8
Metastatic Prostate Carcinoma	NCT04592237	Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer	active not recruiting	PHASE2	120
Metastatic Prostate Neuroendocrine Carcinoma	NCT04592237	Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer	active not recruiting	PHASE2	120
Metastatic Prostate Small Cell Carcinoma	NCT04592237	Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer	active not recruiting	PHASE2	120
Metastatic Solid Tumor	NCT05694715	Combination Therapy in Cancers With Mutations in DNA Repair Genes	recruiting	PHASE1	24
Microsatellite Stable	NCT03983993	Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer	active not recruiting	PHASE2	26
MMR-D/MSI-H Colorectal Cancers	NCT06365970	Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers	withdrawn	PHASE2	0
Molecular Mechanisms of Pharmacological Action	NCT04556071	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	unknown	PHASE2	32
MSI-H Colorectal Cancer	NCT03983993	Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer	active not recruiting	PHASE2	26
Multifocal Breast Carcinoma	NCT04481113	Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer	completed	PHASE1	8
Nasopharyngeal Carcinoma	NCT05162872	Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma	unknown	PHASE2	99
NBN Gene Mutation	NCT04030559	Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects	terminated	PHASE2	11
Neoplasm	NCT02925234	The Drug Rediscovery Protocol (DRUP Trial)	recruiting	PHASE2	1,550
Neoplasms by Histologic Type	NCT04556071	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	unknown	PHASE2	32
Neoplasms by Site	NCT04556071	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	unknown	PHASE2	32
Neoplasms, Glandular and Epithelial	NCT04556071	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	unknown	PHASE2	32
Neuroendocrine Carcinoma	NCT04701307	Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas	active not recruiting	PHASE2	48
Niraparib	NCT05311579	Niraparib Plus Anlotinib for Recurrent Ovarian Cancer	unknown	PHASE2	36
Non Small Cell Lung Cancer	NCT03307785	Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042	completed	PHASE1	60
Non Small Cell Lung Cancer Metastatic	NCT03307785	Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042	completed	PHASE1	60
Non Small Cell Lung Cancer Stage IIIB	NCT03307785	Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042	completed	PHASE1	60
OVARIAN CANCER	NCT06412120	Study Evaluating Safety, Tolerability, and Metabolism of Niraparib	recruiting	PHASE4	70
	NCT06915025	Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer	recruiting	PHASE3	500
	NCT06180356	Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression	recruiting	PHASE2	30
	NCT06433219	Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)	active not recruiting	PHASE2	63
	NCT06594679	A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)	recruiting	PHASE1/PHASE2	73
	NCT06614790	Niraparib Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, OC. The First Poland RWE Study.	recruiting	N/A	300
	NCT06161493	ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors	withdrawn	PHASE1	0
	NCT05961124	Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer	recruiting	PHASE2	40
	NCT05065021	Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor	unknown	PHASE2	40
	NCT05641506	A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer	unknown	PHASE2	50
	NCT05009082	Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer	recruiting	PHASE3	970
	NCT05183984	Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer	recruiting	PHASE2	390
	NCT05187208	PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer	unknown	PHASE4	102
	NCT05198804	A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer	completed	PHASE1/PHASE2	117
	NCT05021562	A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice	completed	N/A	354
	NCT04507841	Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer	active not recruiting	PHASE2	67
	NCT04679064	Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment	unknown	PHASE3	427
	NCT04826198	Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months	terminated	PHASE1/PHASE2	13
	NCT04502602	Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer	active not recruiting	PHASE1	18
	NCT04392102	A Study of Niraparib in Patients With Relapsed Ovarian Cancer	completed	PHASE2	15
	NCT04217798	Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer	unknown	PHASE2	36
	NCT04284852	Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting	completed	PHASE2	20
	NCT04267939	ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer	terminated	PHASE1	14
	NCT03806049	Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer	withdrawn	PHASE3	0
	NCT03891576	Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)	terminated	PHASE2	83
	NCT03752216	NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.	completed	PHASE4	141
	NCT03895788	A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer	unknown	PHASE1	24
	NCT03695380	A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer	completed	PHASE1	77
	NCT03759587	Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer	completed	PHASE2	19
	NCT03759600	Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer	completed	PHASE2	20
	NCT03783949	European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer	completed	PHASE2	122
	NCT03551171	The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer	completed	PHASE1	42
	NCT04785716	Real-life Use of Niraparib in a Patient Access Program in Norway	completed	N/A	106
	NCT03154281	Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast	completed	PHASE1	14
	NCT02657889	Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer	completed	PHASE1/PHASE2	122
	NCT02354586	A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens	completed	PHASE2	463
	NCT02354131	Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer	completed	PHASE1/PHASE2	108
Ovarian Cancer Stage III	NCT05187208	PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer	unknown	PHASE4	102
Ovarian Cancer Stage IV	NCT05187208	PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer	unknown	PHASE4	102
Ovarian Carcinosarcoma	NCT03651206	Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib	recruiting	PHASE2/PHASE3	138
Ovarian Diseases	NCT04556071	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	unknown	PHASE2	32
Ovarian Neoplasm	NCT05751629	Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer	completed	PHASE2	41
P53 Mutation	NCT04159155	A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer	terminated	PHASE2/PHASE3	11
Pancreatic Adenocarcinoma Metastatic	NCT06747845	Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy	recruiting	PHASE2	68
Papillary Serous Endometrial Carcinoma	NCT04080284	Trial of Maintenance With Niraparib- Uterine Serous Carcinoma	completed	PHASE2	22
Penile Carcinoma	NCT05526989	Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma	recruiting	PHASE2	25
Platinum-Resistant Fallopian Tube Carcinoma	NCT05672095	Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer	withdrawn	PHASE1/PHASE2	0
Adenocarcinoma	NCT03840967	A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma	terminated	PHASE2	14
Platinum-resistant Recurrent Clear Cell Ovarian Cancer	NCT05130515	Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.	completed	PHASE2	6
Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor	NCT04734665	Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor	unknown	PHASE2	44
Platinum-sensitive Urothelial Bladder Cancer	NCT04779151	Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab	terminated	PHASE2	51
Platinum Sensitive Ovarian Cancer	NCT01847274	A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer	completed	PHASE3	596
Primary Peritoneal High Grade Serous Adenocarcinoma	NCT03586661	Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	active not recruiting	PHASE1	31
Prognostic Stage I Breast Cancer AJCC v8	NCT04481113	Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer	completed	PHASE1	8
Prognostic Stage IA Breast Cancer AJCC v8	NCT04481113	Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer	completed	PHASE1	8
Prognostic Stage IB Breast Cancer AJCC v8	NCT04481113	Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer	completed	PHASE1	8
Prognostic Stage II Breast Cancer AJCC v8	NCT04481113	Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer	completed	PHASE1	8
Prognostic Stage IIA Breast Cancer AJCC v8	NCT04481113	Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer	completed	PHASE1	8
Prognostic Stage IIB Breast Cancer AJCC v8	NCT04481113	Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer	completed	PHASE1	8
Prognostic Stage III Breast Cancer AJCC v8	NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18
Prognostic Stage IIIA Breast Cancer AJCC v8	NCT04481113	Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer	completed	PHASE1	8
Prognostic Stage IIIB Breast Cancer AJCC v8	NCT04481113	Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer	completed	PHASE1	8
Prognostic Stage IV Breast Cancer AJCC v8	NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18
Progressive Cervix Cancer	NCT04068753	Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer	active not recruiting	PHASE2	66
Progressive Disease	NCT03586661	Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	active not recruiting	PHASE1	31
Prostate Carcinoma Metastatic to the Bone	NCT03076203	Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)	completed	PHASE1	14
Prostatic Neoplasms, Castration-Resistant	NCT03431350	A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer	active not recruiting	PHASE2	136
RAD51 Gene Mutation	NCT04030559	Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects	terminated	PHASE2	11
RAD51B Gene Mutation	NCT06392841	Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations	withdrawn	PHASE2	0
RAD51C Gene Mutation	NCT04030559	Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects	terminated	PHASE2	11
RAD54L Gene Mutation	NCT06392841	Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations	withdrawn	PHASE2	0
Rare Tumor	NCT04423185	PLATFORM Study of Precision Medicine for Rare Tumors	recruiting	PHASE2	770
RAS Wild Type	NCT03983993	Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer	active not recruiting	PHASE2	26
Rectal Neoplasm Malignant	NCT04926324	A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers	terminated	PHASE1/PHASE2	3
Rectal Neoplasms	NCT04926324	A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers	terminated	PHASE1/PHASE2	3
Recurrent Adult Soft Tissue Sarcoma	NCT05238831	SMMART Adaptive Clinical Treatment (ACT) Trial	withdrawn	EARLY_PHASE1	0
Recurrent Astrocytoma	NCT05297864	PARP Inhibition for Gliomas (PI-4G or π4g)	terminated	PHASE2	15
Recurrent Breast Carcinoma	NCT05238831	SMMART Adaptive Clinical Treatment (ACT) Trial	withdrawn	EARLY_PHASE1	0
Recurrent Carcinoma of Ovary	NCT05335993	A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.	active not recruiting	PHASE2	10
Recurrent Cervix Cancer	NCT04068753	Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer	active not recruiting	PHASE2	66
Recurrent Endometrial Serous Adenocarcinoma	NCT05870761	Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma	active not recruiting	PHASE2	8
Recurrent Epithelial Cancer of Ovary	NCT05335993	A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.	active not recruiting	PHASE2	10
Recurrent Epithelial Ovarian Cancer	NCT05335993	A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.	active not recruiting	PHASE2	10
Recurrent Oligodendroglioma	NCT05297864	PARP Inhibition for Gliomas (PI-4G or π4g)	terminated	PHASE2	15
Recurrent Prostate Carcinoma	NCT05238831	SMMART Adaptive Clinical Treatment (ACT) Trial	withdrawn	EARLY_PHASE1	0
Recurrent Small Cell Lung Cancer	NCT05162196	The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer	unknown	PHASE2	57
Recurrent Solid Tumors	NCT06161493	ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors	withdrawn	PHASE1	0
Recurrent/ Advanced Stage Endometrial Cancer Patients	NCT04885413	An Open-label, Single Arm, Phase II Trial of Niraparib in Combination With Anti-PD1（Programmed Cell Death Protein 1） Antibody in Recurrent/ Advanced Stage Endometrial Cancer Patients	unknown	PHASE2	37
Renal Cell Carcinoma	NCT03207347	A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)	completed	PHASE2	37
Residual Disease	NCT03945721	A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients	active not recruiting	PHASE1	21
Sarcoma Uterus	NCT05515575	A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA	active not recruiting	PHASE2	8
Sarcoma,Soft Tissue	NCT05515575	A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA	active not recruiting	PHASE2	8
SCLC,Extensive Stage	NCT05718323	Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC	recruiting	PHASE2	44
Serous Adenocarcinoma	NCT05289648	Niraparib in High-grade Endometrial Cancer Trial	withdrawn	EARLY_PHASE1	0
Serous Ovarian Tumor	NCT06180356	Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression	recruiting	PHASE2	30
SLFN11-positive	NCT05718323	Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC	recruiting	PHASE2	44
Small-cell Lung Cancer	NCT03221400	PEN-866 in Patients With Advanced Solid Malignancies	unknown	PHASE1/PHASE2	340
Small Cell Lung Carcinoma	NCT03221400	PEN-866 in Patients With Advanced Solid Malignancies	unknown	PHASE1/PHASE2	340
Solid Carcinoma	NCT03221400	PEN-866 in Patients With Advanced Solid Malignancies	unknown	PHASE1/PHASE2	340
Solid Tumor, Adult	NCT03209401	Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies	terminated	PHASE1	23
Squamous Cell Carcinoma	NCT03221400	PEN-866 in Patients With Advanced Solid Malignancies	unknown	PHASE1/PHASE2	340
Squamous Cell Carcinoma of the Anus	NCT03221400	PEN-866 in Patients With Advanced Solid Malignancies	unknown	PHASE1/PHASE2	340
Squamous Cell Carcinoma of the Cervix	NCT03221400	PEN-866 in Patients With Advanced Solid Malignancies	unknown	PHASE1/PHASE2	340
Squamous Cell Carcinoma of the Penis	NCT03221400	PEN-866 in Patients With Advanced Solid Malignancies	unknown	PHASE1/PHASE2	340
Squamous Cell Carcinoma of the Vulva	NCT03221400	PEN-866 in Patients With Advanced Solid Malignancies	unknown	PHASE1/PHASE2	340
Stage I Breast Cancer	NCT04584255	Niraparib + Dostarlimab In BRCA Mutated Breast Cancer	active not recruiting	PHASE2	62
Stage II Breast Cancer	NCT04584255	Niraparib + Dostarlimab In BRCA Mutated Breast Cancer	active not recruiting	PHASE2	62
Stage II Pancreatic Cancer AJCC v8	NCT05238831	SMMART Adaptive Clinical Treatment (ACT) Trial	withdrawn	EARLY_PHASE1	0
Stage III Breast Cancer	NCT04584255	Niraparib + Dostarlimab In BRCA Mutated Breast Cancer	active not recruiting	PHASE2	62
Stage III Fallopian Tube Cancer AJCC v8	NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18
Stage III Ovarian Cancer	NCT05961124	Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer	recruiting	PHASE2	40
Stage III Primary Peritoneal Cancer AJCC v8	NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18
Stage III Retroperitoneal Sarcoma AJCC v8	NCT05174455	Niraparib for the Treatment of Leiomyosarcoma	withdrawn	PHASE2	0
Stage IIIA Retroperitoneal Sarcoma AJCC v8	NCT05174455	Niraparib for the Treatment of Leiomyosarcoma	withdrawn	PHASE2	0
Stage IIIB Retroperitoneal Sarcoma AJCC v8	NCT05174455	Niraparib for the Treatment of Leiomyosarcoma	withdrawn	PHASE2	0
Stage IV Breast Cancer	NCT02657889	Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer	completed	PHASE1/PHASE2	122
Stage IV Colorectal Cancer AJCC v8	NCT03983993	Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer	active not recruiting	PHASE2	26
Stage IV Fallopian Tube Cancer AJCC v8	NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18
Stage IV Lung Cancer AJCC v8	NCT03830918	Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy	active not recruiting	PHASE1/PHASE2	59
Stage IV Ovarian Cancer	NCT05961124	Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer	recruiting	PHASE2	40
Stage IV Primary Peritoneal Cancer AJCC v8	NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18
Stage IV Prostate Adenocarcinoma	NCT03076203	Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)	completed	PHASE1	14
Stage IV Prostate Cancer AJCC v8	NCT04592237	Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer	active not recruiting	PHASE2	120
Stage IV Retroperitoneal Sarcoma AJCC v8	NCT05174455	Niraparib for the Treatment of Leiomyosarcoma	withdrawn	PHASE2	0
Stage IVA Lung Cancer AJCC v8	NCT03830918	Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy	active not recruiting	PHASE1/PHASE2	59
Stage IVB Lung Cancer AJCC v8	NCT03830918	Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy	active not recruiting	PHASE1/PHASE2	59
Stage IVB Prostate Cancer AJCC v8	NCT05689021	CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations	active not recruiting	PHASE2	8
Survival Outcomes	NCT05311579	Niraparib Plus Anlotinib for Recurrent Ovarian Cancer	unknown	PHASE2	36
Targeted Therapy	NCT05311579	Niraparib Plus Anlotinib for Recurrent Ovarian Cancer	unknown	PHASE2	36
TNBC - Triple-Negative Breast Cancer	NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	recruiting	PHASE2	5,000
Treatment Efficacy	NCT04508803	Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer	completed	PHASE2	37
Unilateral Breast Carcinoma	NCT04481113	Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer	completed	PHASE1	8
Unresectable Breast Carcinoma	NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18
Unresectable Fallopian Tube Carcinoma	NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18
Unresectable Leiomyosarcoma	NCT05174455	Niraparib for the Treatment of Leiomyosarcoma	withdrawn	PHASE2	0
Unresectable Malignant Solid Neoplasm	NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18
Unresectable Ovarian Carcinoma	NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18
Unresectable Pancreatic Carcinoma	NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18
Unresectable Primary Peritoneal Carcinoma	NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18
Urogenital Neoplasms	NCT04556071	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	unknown	PHASE2	32
Urologic Cancer	NCT05169437	Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors	terminated	PHASE2	22
Urothelial Bladder Cancer	NCT04779151	Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab	terminated	PHASE2	51
Urothelial Cancer	NCT03425201	Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA)	completed	PHASE1/PHASE2	67
Uterine Neoplasm	NCT05289648	Niraparib in High-grade Endometrial Cancer Trial	withdrawn	EARLY_PHASE1	0
Uterine Serous Carcinoma	NCT04080284	Trial of Maintenance With Niraparib- Uterine Serous Carcinoma	completed	PHASE2	22
Uveal Melanoma	NCT03207347	A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)	completed	PHASE2	37
Platinum-Resistant Primary Peritoneal Carcinoma	NCT05672095	Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer	withdrawn	PHASE1/PHASE2	0
Adenocarcinoma of Ovary	NCT05335993	A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.	active not recruiting	PHASE2	10
Adenocarcinoma of the Pancreas	NCT03221400	PEN-866 in Patients With Advanced Solid Malignancies	unknown	PHASE1/PHASE2	340
Adnexal Diseases	NCT04556071	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	unknown	PHASE2	32
Adult Patients With Platinum-sensitive, Relapsed, High Grade Serous Epithelial Ovarian Cancer	NCT04861181	NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients.	terminated	PHASE4	12
Advanced Breast Cancer	NCT02657889	Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer	completed	PHASE1/PHASE2	122
Advanced Breast Carcinoma	NCT05238831	SMMART Adaptive Clinical Treatment (ACT) Trial	withdrawn	EARLY_PHASE1	0
Advanced Microsatellite Stable Colorectal Carcinoma	NCT03983993	Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer	active not recruiting	PHASE2	26
Advanced Ovarian Cancer	NCT07059676	Design and Validation of Plasma Proteins and Cytokine Panels to Identify Markers Associated With Response to Niraparib as Maintenance Treatment After First-line Platinum-based Regimen in Patients With Advanced Ovarian Cancer	not yet recruiting	N/A	120
Advanced Ovarian Carcinoma	NCT05238831	SMMART Adaptive Clinical Treatment (ACT) Trial	withdrawn	EARLY_PHASE1	0
Advanced Pancreatic Carcinoma	NCT05238831	SMMART Adaptive Clinical Treatment (ACT) Trial	withdrawn	EARLY_PHASE1	0
Advanced Prostate Carcinoma	NCT05238831	SMMART Adaptive Clinical Treatment (ACT) Trial	withdrawn	EARLY_PHASE1	0
Advanced Sarcoma	NCT05238831	SMMART Adaptive Clinical Treatment (ACT) Trial	withdrawn	EARLY_PHASE1	0
Advanced Solid Tumors	NCT03497429	A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors	completed	PHASE1	9
Advanced Solid Tumors (Excluding Prostate Cancer)	NCT04267939	ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer	terminated	PHASE1	14
Adverse Events	NCT05311579	Niraparib Plus Anlotinib for Recurrent Ovarian Cancer	unknown	PHASE2	36
Aggressive Variant Prostate Carcinoma	NCT04592237	Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer	active not recruiting	PHASE2	120
Anatomic Stage I Breast Cancer AJCC v8	NCT04481113	Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer	completed	PHASE1	8
Anatomic Stage IA Breast Cancer AJCC v8	NCT04481113	Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer	completed	PHASE1	8
Anatomic Stage IB Breast Cancer AJCC v8	NCT04481113	Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer	completed	PHASE1	8
Anatomic Stage II Breast Cancer AJCC v8	NCT04481113	Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer	completed	PHASE1	8
Anatomic Stage IIA Breast Cancer AJCC v8	NCT04481113	Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer	completed	PHASE1	8
Anatomic Stage IIB Breast Cancer AJCC v8	NCT04481113	Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer	completed	PHASE1	8
Anatomic Stage IIIA Breast Cancer AJCC v8	NCT04481113	Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer	completed	PHASE1	8
Angiogenesis	NCT04556071	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	unknown	PHASE2	32
Angiosarcoma	NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	recruiting	PHASE2	5,000
Anlotinib	NCT05311579	Niraparib Plus Anlotinib for Recurrent Ovarian Cancer	unknown	PHASE2	36
Antineoplastic Agents	NCT04556071	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	unknown	PHASE2	32
ARID1A Gene Mutation	NCT05523440	Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation	terminated	PHASE2	9
Bevacizumab	NCT04556071	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	unknown	PHASE2	32
Biliary Tract Cancer	NCT04779151	Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab	terminated	PHASE2	51
Biliary Tract Carcinoma	NCT04178460	A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment	terminated	PHASE1	60
Biliary Tract Neoplasms	NCT05615818	Personalized Medicine for Advanced Biliary Cancer Patients	recruiting	PHASE3	800
Bladder Cancer	NCT03869190	Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)	completed	PHASE1/PHASE2	272
Brain Metastases	NCT05700721	Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)	recruiting	PHASE2	120
Brain Neoplasms, Adult, Malignant	NCT06388733	A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma	recruiting	PHASE3	450
Brain Tumor	NCT06388733	A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma	recruiting	PHASE3	450
BRCA-Associated Malignant Neoplasm	NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18
BRCA Hereditary Ovarian Carcinoma	NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18
Breast Cancer Metastatic	NCT04240106	Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)	completed	PHASE2	14
Breast Tumor	NCT05169437	Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors	terminated	PHASE2	22
Breast Tumors	NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	recruiting	PHASE2	5,000
CA125	NCT05311579	Niraparib Plus Anlotinib for Recurrent Ovarian Cancer	unknown	PHASE2	36
Cancer of the Endometrium	NCT04080284	Trial of Maintenance With Niraparib- Uterine Serous Carcinoma	completed	PHASE2	22
Carcinoma of Breast	NCT01905592	A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients	terminated	PHASE3	216
Carcinoma, Ovarian Epithelial	NCT04556071	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	unknown	PHASE2	32
Carcinoma, Squamous Cell of Head and Neck	NCT03088059	Biomarker-based Study in R/M SCCHN	unknown	PHASE2	340
Castrate Resistant Prostate Cancer	NCT06527690	Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer	withdrawn	PHASE2	0
Castration-resistant Prostate Cancer	NCT06329830	177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer	withdrawn	PHASE1/PHASE2	0
Castration-Resistant Prostatic Cancer	NCT03748641	A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer	active not recruiting	PHASE3	765
CDK12 Gene Mutation	NCT04030559	Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects	terminated	PHASE2	11
Central Nervous System Cancer	NCT04992013	Niraparib in Tumors Metastatic to the CNS	active not recruiting	PHASE2	20
Cervical Cancer	NCT04395612	Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer	unknown	PHASE2	38
CHEK1 Gene Mutation	NCT04030559	Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects	terminated	PHASE2	11
Chemotherapy	NCT05311579	Niraparib Plus Anlotinib for Recurrent Ovarian Cancer	unknown	PHASE2	36
Clear Cell Renal Cell Carcinoma	NCT04779151	Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab	terminated	PHASE2	51
Colon Tumor, Malignant	NCT05169437	Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors	terminated	PHASE2	22
Deleterious BRCA1 Gene Mutation	NCT03586661	Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	active not recruiting	PHASE1	31
Deleterious BRCA2 Gene Mutation	NCT03586661	Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	active not recruiting	PHASE1	31
Deleterious HRR Gene Mutation	NCT06392841	Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations	withdrawn	PHASE2	0
Deleterious PALB2 Gene Mutation	NCT04584255	Niraparib + Dostarlimab In BRCA Mutated Breast Cancer	active not recruiting	PHASE2	62
DNA Damage Response Gene Mutation	NCT04030559	Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects	terminated	PHASE2	11
DNA Repair Gene Mutation	NCT04030559	Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects	terminated	PHASE2	11
Early-stage Breast Cancer	NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	recruiting	PHASE2	5,000
Efficacy	NCT06237205	Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency	not yet recruiting	PHASE2	33
Endocrine Gland Neoplasms	NCT04556071	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	unknown	PHASE2	32
Endocrine System Diseases	NCT04556071	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	unknown	PHASE2	32
Endometrial Carcinosarcoma	NCT03651206	Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib	recruiting	PHASE2/PHASE3	138
Enzyme Inhibitors	NCT04556071	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	unknown	PHASE2	32
Ewing Sarcoma	NCT02044120	ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma	completed	PHASE1	34
Extensive Stage Lung Small Cell Carcinoma	NCT03830918	Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy	active not recruiting	PHASE1/PHASE2	59
Fallopian Tube Neoplasms	NCT04556071	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	unknown	PHASE2	32
FANCD2 Gene Mutation	NCT04030559	Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects	terminated	PHASE2	11
FANCL Gene Mutation	NCT04030559	Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects	terminated	PHASE2	11
Gastro-oesophageal Adenocarcinoma	NCT04779151	Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab	terminated	PHASE2	51
Gastroesophageal Junction Adenocarcinoma	NCT03221400	PEN-866 in Patients With Advanced Solid Malignancies	unknown	PHASE1/PHASE2	340
GEN1 Gene Mutation	NCT04030559	Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects	terminated	PHASE2	11
Genital Diseases, Female	NCT04556071	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	unknown	PHASE2	32
Genital Neoplasms, Female	NCT04556071	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	unknown	PHASE2	32
Germline BRCA1 Gene Mutation	NCT04584255	Niraparib + Dostarlimab In BRCA Mutated Breast Cancer	active not recruiting	PHASE2	62
Germline BRCA2 Gene Mutation	NCT04584255	Niraparib + Dostarlimab In BRCA Mutated Breast Cancer	active not recruiting	PHASE2	62
Glioblastoma Multiforme	NCT05076513	Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma	active not recruiting	EARLY_PHASE1	42
Glioblastoma Multiforme of Brain	NCT05076513	Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma	active not recruiting	EARLY_PHASE1	42
Glioma	NCT05076513	Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma	active not recruiting	EARLY_PHASE1	42
Gonadal Disorders	NCT04556071	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	unknown	PHASE2	32
Hepatic Impairment	NCT03359850	Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients	completed	PHASE1	17
HER2-negative Metastatic Breast Cancer	NCT05261269	A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer	completed	PHASE1	30
HER2-positive Breast Cancer	NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	recruiting	PHASE2	5,000
HER2 Negative Breast Adenocarcinoma	NCT04481113	Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer	completed	PHASE1	8
HER2 Positive Breast Carcinoma	NCT03368729	Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer	active not recruiting	PHASE1/PHASE2	46
High Grade Endometrioid Cancer	NCT05065021	Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor	unknown	PHASE2	40
High Grade Serous Cancer	NCT05065021	Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor	unknown	PHASE2	40

All Niraparib Clinical Trials (199)

NCT ID	Title	Status	Phase	Enrollment	Sponsor
NCT06412120	Study Evaluating Safety, Tolerability, and Metabolism of Niraparib	recruiting	PHASE4	70	University of Miami
NCT06392841	Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations	withdrawn	PHASE2	0	Qian Qin
NCT06682780	A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours	recruiting	PHASE1/PHASE2	320	LaNova Medicines Limited
NCT07059676	Design and Validation of Plasma Proteins and Cytokine Panels to Identify Markers Associated With Response to Niraparib as Maintenance Treatment After First-line Platinum-based Regimen in Patients With Advanced Ovarian Cancer	not yet recruiting	N/A	120	Clinica Universidad de Navarra, Universidad de Navarra
NCT06953323	A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors	recruiting	PHASE1/PHASE2	86	Wigen Biomedicine Technology (Shanghai) Co., Ltd.
NCT06915025	Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer	recruiting	PHASE3	500	Imunon
NCT06747845	Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy	recruiting	PHASE2	68	Abramson Cancer Center at Penn Medicine
NCT06527690	Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer	withdrawn	PHASE2	0	Latin American Cooperative Oncology Group
NCT06887933	A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer	not yet recruiting	PHASE4	67	GlaxoSmithKline
NCT05672095	Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer	withdrawn	PHASE1/PHASE2	0	City of Hope Medical Center
NCT06365970	Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers	withdrawn	PHASE2	0	Ibrahim Halil Sahin
NCT06180356	Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression	recruiting	PHASE2	30	MedSIR
NCT06329830	177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer	withdrawn	PHASE1/PHASE2	0	Baptist Health South Florida
NCT06433219	Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)	active not recruiting	PHASE2	63	EMD Serono Research & Development Institute, Inc.
NCT06258018	Niraparib and Temozolomide in Patients Glioblastoma	not yet recruiting	PHASE1/PHASE2	86	Armando Santoro, MD
NCT06594679	A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)	recruiting	PHASE1/PHASE2	73	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
NCT06614790	Niraparib Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, OC. The First Poland RWE Study.	recruiting	N/A	300	Pomeranian Medical University Szczecin
NCT05615818	Personalized Medicine for Advanced Biliary Cancer Patients	recruiting	PHASE3	800	UNICANCER
NCT05990192	SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy	recruiting	PHASE2	42	Institute of Cancer Research, United Kingdom
NCT06388733	A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma	recruiting	PHASE3	450	Ivy Brain Tumor Center
NCT05289648	Niraparib in High-grade Endometrial Cancer Trial	withdrawn	EARLY_PHASE1	0	Sir Mortimer B. Davis - Jewish General Hospital
NCT06212583	High-Risk Metachronous Oligometastatic Prostate Cancer Trial	active not recruiting	PHASE2	88	University of Maryland, Baltimore
NCT05689021	CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations	active not recruiting	PHASE2	8	Mayo Clinic
NCT06237205	Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency	not yet recruiting	PHASE2	33	Korea University Anam Hospital
NCT06161493	ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors	withdrawn	PHASE1	0	Haider Mahdi
NCT05718323	Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC	recruiting	PHASE2	44	ETOP IBCSG Partners Foundation
NCT05174455	Niraparib for the Treatment of Leiomyosarcoma	withdrawn	PHASE2	0	David Liebner, MD
NCT05784012	Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma	active not recruiting	PHASE1/PHASE2	34	Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
NCT06141265	Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab	recruiting	PHASE2	116	Peking University Cancer Hospital & Institute
NCT05126342	Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi	withdrawn	PHASE2	0	AGO Research GmbH
NCT06077877	A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors	active not recruiting	PHASE1/PHASE2	42	GlaxoSmithKline
NCT05870761	Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma	active not recruiting	PHASE2	8	Casey Cosgrove
NCT05666349	Reirradiation and Niraparib in Patients With Recurrent Glioblastoma	withdrawn	PHASE1	0	University College, London
NCT05412706	Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy	withdrawn	PHASE2	0	Ospedale Policlinico San Martino
NCT05961124	Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer	recruiting	PHASE2	40	Sunnybrook Health Sciences Centre
NCT05601440	Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer	recruiting	PHASE2	484	Canadian Cancer Trials Group
NCT05700721	Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)	recruiting	PHASE2	120	M.D. Anderson Cancer Center
NCT04149145	Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer	withdrawn	PHASE1	0	University of Alabama at Birmingham
NCT05694715	Combination Therapy in Cancers With Mutations in DNA Repair Genes	recruiting	PHASE1	24	University of California, San Francisco
NCT05406700	Niraparib In Recurrent IDH 1/2 Gliomas	active not recruiting	EARLY_PHASE1	16	Massachusetts General Hospital
NCT05519670	A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr	not yet recruiting	PHASE1/PHASE2	72	Institut Paoli-Calmettes
NCT05065021	Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor	unknown	PHASE2	40	University Health Network, Toronto
NCT05523440	Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation	terminated	PHASE2	9	University of Oklahoma
NCT05238831	SMMART Adaptive Clinical Treatment (ACT) Trial	withdrawn	EARLY_PHASE1	0	OHSU Knight Cancer Institute
NCT05641506	A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer	unknown	PHASE2	50	Sichuan Cancer Hospital and Research Institute
NCT05526989	Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma	recruiting	PHASE2	25	H. Lee Moffitt Cancer Center and Research Institute
NCT05442749	Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer	terminated	PHASE2	2	Centre Leon Berard
NCT05009082	Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer	recruiting	PHASE3	970	AGO Study Group
NCT05461690	Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency	unknown	PHASE2	50	Zhejiang Cancer Hospital
NCT05515575	A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA	active not recruiting	PHASE2	8	Memorial Sloan Kettering Cancer Center
NCT05335993	A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.	active not recruiting	PHASE2	10	CanariaBio Inc.
NCT05455424	Niraparib Efficacy in Patient With Unresectable Mesothelioma	completed	PHASE2	88	University Hospital Southampton NHS Foundation Trust
NCT04926324	A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers	terminated	PHASE1/PHASE2	3	University of Iowa
NCT05385068	A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi	unknown	PHASE2	35	Peking Union Medical College Hospital
NCT05162196	The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer	unknown	PHASE2	57	Wuhan University
NCT05297864	PARP Inhibition for Gliomas (PI-4G or π4g)	terminated	PHASE2	15	University of Oklahoma
NCT05232006	PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers	not yet recruiting	PHASE2	12	Assistance Publique - Hôpitaux de Paris
NCT06964165	A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)	terminated	PHASE2	36	Tesaro, Inc.
NCT04992013	Niraparib in Tumors Metastatic to the CNS	active not recruiting	PHASE2	20	Massachusetts General Hospital
NCT05311579	Niraparib Plus Anlotinib for Recurrent Ovarian Cancer	unknown	PHASE2	36	Lei Li
NCT05169437	Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors	terminated	PHASE2	22	Tempus AI
NCT05261269	A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer	completed	PHASE1	30	Dantari, Inc.
NCT05183984	Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer	recruiting	PHASE2	390	ARCAGY/ GINECO GROUP
NCT05187208	PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer	unknown	PHASE4	102	Seoul National University Hospital
NCT05198804	A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer	completed	PHASE1/PHASE2	117	K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT05130515	Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.	completed	PHASE2	6	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT05076513	Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma	active not recruiting	EARLY_PHASE1	42	Nader Sanai
NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	PHASE1	18	University of Washington
NCT04895046	Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma	withdrawn	PHASE2	0	Walid Shaib, MD
NCT04812366	Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer	recruiting	PHASE2	315	University of British Columbia
NCT05021562	A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice	completed	N/A	354	Takeda
NCT04991480	A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors	completed	PHASE1	93	Artios Pharma Ltd
NCT04986371	Real-world Study of Niraparib Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer	unknown	N/A	300	Ling-Ying Wu
NCT04947254	Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer	recruiting	PHASE2	200	M.D. Anderson Cancer Center
NCT05162872	Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma	unknown	PHASE2	99	Sun Yat-sen University
NCT04837209	Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer	active not recruiting	PHASE2	32	Massachusetts General Hospital
NCT04734665	Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor	unknown	PHASE2	44	Yonsei University
NCT04885413	An Open-label, Single Arm, Phase II Trial of Niraparib in Combination With Anti-PD1（Programmed Cell Death Protein 1） Antibody in Recurrent/ Advanced Stage Endometrial Cancer Patients	unknown	PHASE2	37	Sun Yat-sen University
NCT04915755	Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease	active not recruiting	PHASE3	40	GlaxoSmithKline
NCT04481113	Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer	completed	PHASE1	8	OHSU Knight Cancer Institute
NCT04716686	Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma	recruiting	PHASE2	83	Shandong University
NCT04861181	NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients.	terminated	PHASE4	12	Hospices Civils de Lyon
NCT04641247	A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study	recruiting	PHASE2	30	GlaxoSmithKline
NCT04779151	Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab	terminated	PHASE2	51	Gustave Roussy, Cancer Campus, Grand Paris
NCT04764084	Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors	unknown	PHASE1	52	Peking University Cancer Hospital & Institute
NCT04762901	LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer	withdrawn	PHASE1	0	Wake Forest University Health Sciences
NCT04774406	Arterial Hypertension Related to PARP Inhibitors (ArteRIB)	completed	N/A	2,336	University Hospital, Caen
NCT04681469	Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC	recruiting	PHASE2	49	Gruppo Oncologico del Nord-Ovest
NCT04701307	Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas	active not recruiting	PHASE2	48	M.D. Anderson Cancer Center
NCT04715620	Niraparib Combined With Radiotherapy in rGBM	unknown	PHASE2	30	Tianjin Huanhu Hospital
NCT04507841	Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer	active not recruiting	PHASE2	67	Tongji Hospital
NCT04592237	Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer	active not recruiting	PHASE2	120	M.D. Anderson Cancer Center
NCT04493060	Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer	completed	PHASE2	22	Mayo Clinic
NCT04940637	UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC	unknown	PHASE2	70	University of Turin, Italy
NCT04584255	Niraparib + Dostarlimab In BRCA Mutated Breast Cancer	active not recruiting	PHASE2	62	Dana-Farber Cancer Institute
NCT04655183	Study of M4344 in Combination With Niraparib	withdrawn	PHASE1/PHASE2	0	EMD Serono Research & Development Institute, Inc.
NCT04679064	Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment	unknown	PHASE3	427	Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NCT04159155	A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer	terminated	PHASE2/PHASE3	11	University Health Network, Toronto
NCT04577833	A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer	active not recruiting	PHASE1	136	Janssen Research & Development, LLC
NCT04556071	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	unknown	PHASE2	32	Xiaoxiang Chen
NCT04194554	A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer	active not recruiting	PHASE1/PHASE2	102	University of Michigan Rogel Cancer Center
NCT04313504	Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC	completed	PHASE2	10	Trisha Wise-Draper
NCT04475939	Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer	completed	PHASE3	666	GlaxoSmithKline
NCT04185831	A MolEcularly Guided Anti-Cancer Drug Off-Label Trial	active not recruiting	PHASE2	167	Uppsala University Hospital
NCT04288687	A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects	completed	PHASE2	11	Abramson Cancer Center at Penn Medicine
NCT04544995	Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)	terminated	PHASE1	47	GlaxoSmithKline
NCT04826198	Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months	terminated	PHASE1/PHASE2	13	Gustave Roussy, Cancer Campus, Grand Paris
NCT06827353	Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Without Homologous Recombination Deficiency	recruiting	N/A	300	Centre Hospitalier Universitaire de Nīmes
NCT04546373	Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer	completed	N/A	316	Grupo Español de Investigación en Cáncer de Ovario
NCT04497844	A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)	active not recruiting	PHASE3	696	Janssen Research & Development, LLC
NCT04508803	Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer	completed	PHASE2	37	Fudan University
NCT04341181	ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling	recruiting	PHASE2	300	Ulrik Lassen
NCT04502602	Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer	active not recruiting	PHASE1	18	Virginia Commonwealth University
NCT04423185	PLATFORM Study of Precision Medicine for Rare Tumors	recruiting	PHASE2	770	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT04392102	A Study of Niraparib in Patients With Relapsed Ovarian Cancer	completed	PHASE2	15	Zai Lab (Shanghai) Co., Ltd.
NCT04409002	Niraparib + Dostarlimab + RT in Pancreatic Cancer	completed	PHASE2	18	Massachusetts General Hospital
NCT03651206	Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib	recruiting	PHASE2/PHASE3	138	ARCAGY/ GINECO GROUP
NCT04235101	Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors	completed	PHASE1	32	Byondis B.V.
NCT04240106	Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)	completed	PHASE2	14	MedSIR
NCT04376073	Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer	unknown	PHASE2	40	Jihong Liu
NCT04217798	Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer	unknown	PHASE2	36	Peking Union Medical College Hospital
NCT04395612	Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer	unknown	PHASE2	38	Chongqing University Cancer Hospital
NCT04284852	Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting	completed	PHASE2	20	The University of Hong Kong
NCT04068753	Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer	active not recruiting	PHASE2	66	University of Oklahoma
NCT04267939	ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer	terminated	PHASE1	14	Bayer
NCT04030559	Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects	terminated	PHASE2	11	University of California, Davis
NCT04178460	A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment	terminated	PHASE1	60	Zai Lab (Shanghai) Co., Ltd.
NCT03806049	Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer	withdrawn	PHASE3	0	Nordic Society of Gynaecological Oncology - Clinical Trials Unit
NCT04080284	Trial of Maintenance With Niraparib- Uterine Serous Carcinoma	completed	PHASE2	22	Northwell Health
NCT04221503	Niraparib/TTFields in GBM	active not recruiting	PHASE2	30	Abramson Cancer Center at Penn Medicine
NCT04170153	Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)	active not recruiting	PHASE1	161	EMD Serono Research & Development Institute, Inc.
NCT06086665	The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer	completed	N/A	850	Asan Medical Center
NCT03891576	Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)	terminated	PHASE2	83	Mario Negri Institute for Pharmacological Research
NCT03983226	Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)	recruiting	PHASE2	167	Shanghai Gynecologic Oncology Group
NCT03983993	Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer	active not recruiting	PHASE2	26	Emory University
NCT03425201	Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA)	completed	PHASE1/PHASE2	67	Fundacion CRIS de Investigación para Vencer el Cáncer
NCT04037254	Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring	completed	PHASE1/PHASE2	22	NRG Oncology
NCT03955471	Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer	terminated	PHASE2	41	Tesaro, Inc.
NCT03368729	Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer	active not recruiting	PHASE1/PHASE2	46	University of Alabama at Birmingham
NCT03945084	Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy	completed	PHASE2	58	University of Turin, Italy
NCT03981796	A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer	active not recruiting	PHASE3	785	Tesaro, Inc.
NCT03945721	A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients	active not recruiting	PHASE1	21	Massachusetts General Hospital
NCT03840967	A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma	terminated	PHASE2	14	Shadia Jalal, MD
NCT03891615	Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer	unknown	PHASE1	30	Massachusetts General Hospital
NCT03869190	Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)	completed	PHASE1/PHASE2	272	Hoffmann-La Roche
NCT03586661	Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	active not recruiting	PHASE1	31	M.D. Anderson Cancer Center
NCT03752216	NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.	completed	PHASE4	141	ARCAGY/ GINECO GROUP
NCT03925350	Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation	unknown	PHASE2	41	California Pacific Medical Center Research Institute
NCT03830918	Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy	active not recruiting	PHASE1/PHASE2	59	Jonsson Comprehensive Cancer Center
NCT03768063	A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study	active not recruiting	PHASE3	1,000	Hoffmann-La Roche
NCT03903835	ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer	recruiting	PHASE3	750	Karolinska Institutet
NCT03654833	Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma	unknown	PHASE2	186	University of Leicester
NCT03748641	A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer	active not recruiting	PHASE3	765	Janssen Research & Development, LLC
NCT03553004	Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial	unknown	PHASE2	18	University of Kansas Medical Center
NCT03895788	A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer	unknown	PHASE1	24	Hunan Cancer Hospital
NCT03695380	A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer	completed	PHASE1	77	Hoffmann-La Roche
NCT05734911	Effectiveness and Safety of Niraparib as First-line Maintenance Therapy for Ovarian Cancer: a Real-world Study	completed	N/A	199	Zhongda Hospital
NCT03759587	Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer	completed	PHASE2	19	Takeda
NCT03759600	Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer	completed	PHASE2	20	Takeda
NCT03783949	European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer	completed	PHASE2	122	Universitaire Ziekenhuizen KU Leuven
NCT03598270	Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer	completed	PHASE3	417	Grupo Español de Investigación en Cáncer de Ovario
NCT05751629	Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer	completed	PHASE2	41	Tesaro, Inc.
NCT03574779	A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer	completed	PHASE2	77	Tesaro, Inc.
NCT03602859	A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer	active not recruiting	PHASE3	1,400	Tesaro, Inc.
NCT03601923	Niraparib in Patients With Pancreatic Cancer	completed	PHASE2	32	Dana-Farber Cancer Institute
NCT03207347	A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)	completed	PHASE2	37	University of Florida
NCT02826512	A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients	terminated	PHASE2	9	The Netherlands Cancer Institute
NCT03329937	Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer	completed	PHASE1	21	Tesaro, Inc.
NCT03497429	A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors	completed	PHASE1	9	Takeda
NCT03431350	A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer	active not recruiting	PHASE2	136	Janssen Research & Development, LLC
NCT03359850	Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients	completed	PHASE1	17	Tesaro, Inc.
NCT03404960	Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy	completed	PHASE1/PHASE2	104	University of Pennsylvania
NCT03551171	The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer	completed	PHASE1	42	Zai Lab (Shanghai) Co., Ltd.
NCT03326193	A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy	completed	PHASE2	105	Tesaro, Inc.
NCT03329001	Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule	completed	PHASE1	236	Tesaro, Inc.
NCT03088059	Biomarker-based Study in R/M SCCHN	unknown	PHASE2	340	European Organisation for Research and Treatment of Cancer - EORTC
NCT03016338	Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer	unknown	PHASE2	51	University Health Network, Toronto
NCT03209401	Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies	terminated	PHASE1	23	Georgetown University
NCT03307785	Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042	completed	PHASE1	60	Tesaro, Inc.
NCT03308942	Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants	completed	PHASE2	53	Tesaro, Inc.
NCT03076203	Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)	completed	PHASE1	14	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03221400	PEN-866 in Patients With Advanced Solid Malignancies	unknown	PHASE1/PHASE2	340	Tarveda Therapeutics
NCT04785716	Real-life Use of Niraparib in a Patient Access Program in Norway	completed	N/A	106	Kristina Lindemann
NCT03154281	Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast	completed	PHASE1	14	Avera McKennan Hospital & University Health Center
NCT02924766	A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)	completed	PHASE1	34	Janssen Research & Development, LLC
NCT02925234	The Drug Rediscovery Protocol (DRUP Trial)	recruiting	PHASE2	1,550	The Netherlands Cancer Institute
NCT02854436	An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies	completed	PHASE2	289	Janssen Research & Development, LLC
NCT02655016	A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy	active not recruiting	PHASE3	733	Tesaro, Inc.
NCT02657889	Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer	completed	PHASE1/PHASE2	122	Tesaro, Inc.
NCT02500901	Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)	terminated	PHASE1	2	Paul Mathew, MD
NCT02354586	A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens	completed	PHASE2	463	Tesaro, Inc.
NCT02476552	Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With Cancer	completed	PHASE1	12	Tesaro, Inc.
NCT02354131	Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer	completed	PHASE1/PHASE2	108	Nordic Society of Gynaecological Oncology - Clinical Trials Unit
NCT02044120	ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma	completed	PHASE1	34	Sarcoma Alliance for Research through Collaboration
NCT01905592	A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients	terminated	PHASE3	216	Tesaro, Inc.
NCT01847274	A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer	completed	PHASE3	596	Tesaro, Inc.
NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	recruiting	PHASE2	5,000	QuantumLeap Healthcare Collaborative
NCT03025867	Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer	approved for marketing	N/A	0	Tesaro, Inc.
NCT05401214	Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)	approved for marketing	N/A	0	Janssen Research & Development, LLC

Where to Participate: All Niraparib Trial Sites in the U.S. (94 sites across 30 states)

Every actively recruiting Niraparibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	University of Alabama at Birmingham	Birmingham35294	NCT01042379	Map
AL	University of Alabama at Birmingham	Birmingham35233	NCT06388733	Map
AZ	Ivy Brain Tumor Center	Phoenix85013	NCT06388733	Map
CA	University of California - Davis, Comprehensive Cancer Center	Davis95817	NCT01042379	Map
CA	City of Hope	Duarte91010	NCT01042379	Map
CA	GSK Investigational Site	Encinitas92024	NCT04641247	Map
CA	Moores UCSD Cancer Center	La Jolla92093	NCT06388733	Map
CA	Scripps Cancer Center	La Jolla92037	NCT06388733	Map
CA	University of California San Diego	La Jolla92093-0698	NCT01042379	Map
CA	GSK Investigational Site	Los Angeles90048	NCT04641247	Map
CA	University of Southern California	Los Angeles90033	NCT01042379	Map
CA	HOAG Memorial Hospital Presbyterian	Newport Beach92663	NCT01042379	Map
CA	University of California Davis	Sacramento95817	NCT04812366	Map
CA	University of California San Francisco (UCSF)	San Francisco94115	NCT01042379	Map
CA	University of California, San Francisco	San Francisco94143	NCT05694715	Map
CO	University of Colorado Cancer Center	Aurora80045	NCT01042379	Map
CT	Smilow Cancer Hospital at Yale New Haven	Guilford06437	NCT06388733	Map
CT	Yale Cancer Center	New Haven06510	NCT01042379	Map
DC	Georgetown University Medical Center	Washington D.C.20007	NCT01042379	Map
FL	Broward Health	Fort Lauderdale33316	NCT06412120	Map
FL	University of Florida Jacksonville	Jacksonville32209	NCT06412120	Map
FL	University of Miami	Miami33136	NCT06412120	Map
FL	Advent Health	Orlando32804	NCT06915025	Map
FL	H. Lee Moffitt Cancer Center and Research Institute	Tampa33612	NCT01042379	Map
FL	Moffitt Cancer Center	Tampa33612	NCT05526989	Map
FL	Moffitt Cancer Center	Tampa33612	NCT01042379	Map
GA	GSK Investigational Site	Atlanta30342	NCT04641247	Map
GA	Winship Cancer Institute of Emory University	Atlanta30322	NCT01042379	Map
IL	University of Chicago	Chicago60453	NCT01042379	Map
IL	GSK Investigational Site	Harvey60426	NCT04641247	Map
IL	Loyola University	Maywood60153	NCT01042379	Map
IN	Indiana University	Indianapolis46202	NCT06388733	Map
LA	The NeuroMedical Center	Baton Rouge70809	NCT06388733	Map
ME	MaineHealth Maine Medical Center Care	South Portland04106	NCT06388733	Map
MA	Brigham & Women's Hospital	Boston02115	NCT04812366	Map
MA	GSK Investigational Site	Boston02115	NCT04641247	Map
MA	Tufts Medical Center	Boston02111	NCT06388733	Map
MI	University of Michigan Health	Ann Arbor48109-5946	NCT04812366	Map
MI	University of Michigan Rogel Cancer Center	Ann Arbor48109	NCT06388733	Map
MI	GSK Investigational Site	Grand Rapids60637-1470	NCT04641247	Map
MI	Herbert-Herman Cancer Center, Sparrow Hospital	Lansing48912	NCT01042379	Map
MN	Allina Health	Minneapolis55407	NCT06388733	Map
MN	University of Minnesota	Minneapolis55455	NCT01042379	Map
MN	University of Minnesota Health Clinics and Surgery Center, Minneapolis	Minneapolis55455	NCT06388733	Map
MN	Mayo Clinic	Rochester55905	NCT01042379	Map
MN	Metro Minnesota Community Oncology Research Consortium, Hennepin County Medical Center	Saint Louis Park55416	NCT01042379	Map
MO	Saint Lukes Neuro Oncology	Kansas City64111	NCT06388733	Map
MO	Washington University School of Medicine in St. Louis	St Louis63110	NCT06915025	Map
MO	Washington University, School of Medicine	St Louis63110	NCT06388733	Map
NJ	GSK Investigational Site	Morristown07962-1956	NCT04641247	Map
NJ	Jersey Shore University Medical Center	Neptune City07753	NCT06388733	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08903	NCT01042379	Map
NJ	Atlantic Health System	Summit07901	NCT06388733	Map
NY	Roswell Park Cancer Institute	Buffalo14263	NCT01042379	Map
NY	GSK Investigational Site	Lake Success11042	NCT04641247	Map
NY	Northwell Health	New Hyde Park11042	NCT06388733	Map
NY	Columbia University Medical Center	New York10032	NCT01042379	Map
NY	Laura and Isaac Perlmutter Cancer Center / NYU Langone Health	New York10016	NCT01042379	Map
NY	New York University Ambulatory Care Center	New York10016	NCT06388733	Map
NY	University of Rochester Wilmot Cancer Institute	Rochester14642	NCT01042379	Map
NY	Montefiore Medical Center	The Bronx10467	NCT01042379	Map
NY	Montefiore Medical Center	The Bronx10461	NCT06388733	Map
NC	GSK Investigational Site	Charlotte28204	NCT04641247	Map
NC	Duke Cancer Center Brain Tumor Clinic	Durham27710	NCT06388733	Map
NC	Wake Forest Baptist Comprehensive Cancer Center	Winston-Salem27157	NCT01042379	Map
NC	Wake Forest Baptist Health	Winston-Salem27157	NCT06388733	Map
OH	University of Cincinnati Cancer Institute	Cincinnati45267	NCT06388733	Map
OH	Cleveland Clinic	Cleveland44106	NCT01042379	Map
OH	The Cleveland Clinic Foundation	Cleveland44195	NCT06388733	Map
OH	The Ohio State University	Columbus43210	NCT06388733	Map
OH	The Ohio State University, Stefanie Spielman Comprehensive Breast Center	Columbus43212	NCT01042379	Map
OR	Oregon Health & Science Institute (OHSU)	Portland97239	NCT01042379	Map
OR	Providence Cancer Institute	Portland97213	NCT06915025	Map
OR	Providence Portland Medical Center	Portland97213	NCT06388733	Map
PA	Thomas Jefferson University	Philadelphia19107	NCT06388733	Map
PA	University of Pennsylvania (U Penn)	Philadelphia19104	NCT01042379	Map
PA	University of Pennsylvania, Abramson Cancer Center	Philadelphia19104	NCT06747845	Map
PA	University of Pittsburgh Medical Center Health System	Pittsburgh15232	NCT06388733	Map
SC	Medical University of South Carolina - Department of Neurosurgery	Charleston29425	NCT06388733	Map
SD	Sanford Clinical Research	Sioux Falls57104	NCT01042379	Map
SD	Sanford Health	Sioux Falls57104	NCT06915025	Map
TN	Erlanger Health	Chattanooga37403	NCT06915025	Map
TX	M D Anderson Cancer Center	Houston77030	NCT04947254	Map
TX	M D Anderson Cancer Center	Houston77030	NCT05700721	Map
TX	MD Anderson Cancer Center	Houston77030	NCT05526989	Map
TX	U.T. MD Anderson Cancer Center	Houston77030	NCT04812366	Map
TX	Baylor Scott & White Health	Temple76508	NCT06388733	Map
UT	Huntsman Cancer Institute, University of Utah	Salt Lake City84112	NCT01042379	Map
VT	The University of Vermont Medical Center	Burlington05401	NCT06388733	Map
WA	Fred Hutchinson Cancer Center	Seattle98109	NCT04812366	Map
WA	University of Washington Medical Center	Seattle98109	NCT06388733	Map
WA	Providence Sacred Heart Medical Center & Children's Hospital	Spokane99204	NCT06915025	Map
WI	University of Wisconsin Cancer Center	Madison53706	NCT06388733	Map
WI	Froedtert and The Medical College of Wisconsin	Milwaukee53226	NCT06915025	Map

Browse Niraparib Trials by State

Texas clinical trials Washington clinical trials Massachusetts clinical trials Pennsylvania clinical trials Oregon clinical trials California clinical trials Ohio clinical trials Florida clinical trials Minnesota clinical trials New York clinical trials

niraparibovarian cancerovarian neoplasmsbreast cancerfallopian tube cancerneoplasmsclinical trials

Data sourced from the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI). Report generated June 2, 2026.

What Is Niraparib?

Uses and Conditions Under Study

Dosing

Side Effects

Clinical Trial Results

Currently Recruiting Trials

Where to Participate

Development Timeline

Niraparib Development Timeline

Conditions Under Study

All Niraparib Clinical Trials (199)

Sponsors

Where to Participate: All Niraparib Trial Sites in the U.S. (94 sites across 30 states)

Browse Niraparib Trials by State